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iABSTRACT
Tumour invasion is the key element in the high rate of mortality and morbidity in glioma 
patients. The increased levels of expression of the cell surface adhesion molecules 
CD44/CD155 on neoplastic cells have been highlighted in several studies; both playing a 
role in glioma invasion. CD44; originally described as the lymphocyte homing receptor, is 
a cell adhesion molecule with two isoforms with respective molecular weights of 80-90 
kDa and 150kDa. CD44 mediates glioma cell adhesion and invasion through its interaction 
with hyaluronic acid (HA). CD155, also known as the poliovirus receptor, is a 
transmembrane glycoprotein, the ectodomain of which mediates cell attachment to the 
extracellular matrix component, vitronectin. Within the scope of this thesis, an up-
regulation of CD44 and CD155 has been demonstrated on established cell line (SNB-19) 
and early passage cultures of biopsy-derived glioma (UPAB and UPMC) using 
immunocytochemistry and flow cytometry. TIRF microscopy has revealed that CD44 and 
CD155 are located in close proximity in all the GBM cells studied. CD44 antibody 
blocking and gene silencing resulted in a higher level of inhibition of invasion than that for 
CD155 when assessed using the Transwell assay. Interference with combined 
CD44/CD155 resulted in 86% inhibition of invasion in post-transfected cells. Live cell 
imaging showed reduced speed of motility and distance travelled in knocked-down cells 
over their controls. Both siRNA CD44 and siRNA CD155 cells were devoid of filopodia 
and were rounder in morphology compared to wild type cells. The ECM cell adhesion 
array demonstrated wild type cells adhered most efficiently to laminin whereas siRNA-
treated cells showed decreased adhesive potential on most of the ECMs used. The BrdU 
cell proliferation assay showed a higher proliferative rate of siRNA CD44 and siRNA 
ii
CD155 treated cells was achieved and this was inversely correlated with the reduced 
invasion of these cells. Confocal microscopy showed distinct overlapping of CD155 and 
the integrins (β1, αvβ1 and αvβ3) on extending processes of the GBM cells whereas siRNA-
transfected cells showed consequent reduction in expression level of the integrins with no 
specific staining patterns. RHO GTPases assay showed reduced expression levels of 
Cdc42, Rac1/2/3 and RhoA in siRNA transfected CD44 and CD155 cells. No change in 
expression level of RhoC was observed in siRNA CD155 cells compared to the control 
cells and the expression levels of RhoB were unchanged in both transfected and control 
cells. Joint CD44/CD155 approaches may merit further study in targeting infiltrating 
glioma cells in therapeutic protocols.
iii
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1.1 Cellular nature of the brain 
The two major groups of cells of the adult central nervous system (CNS) are the neurons 
and glial cells. All neurons share the same basic architecture but can be classified into at 
least a thousand different types (Kandel, 2000). Glial cells are divided into microglia 
(phagocytes involved in inflammatory responses (Innamorato, 2009) and macroglia 
(neuroectodermal in origin), which include astrocytes (Butt, 2005), oligodendrocytes and 
ependymal cells. Astrocytes are involved in trophic and metabolic support for neurons, 
neuronal survival and differentiation, neuronal guidance, neurite outgrowth and 
synaptogenesis. They also participate in brain homeostasis (Araque, 2008). 
Oligodendrocytes produce myelin which is the lipid-enriched dielectric that forms a 
membrane around axons essential for salutatory conduction of action potentials in the CNS 
(Jakovcevski, 2009). Ependymal cells are a specialized epithelial cell type lining the 
ventricles of the brain and are involved in transport of cerebro spinal fluid and in brain 
homeostasis (Spassky, 2005). 
 
1.2 Brain tumours and Epidemiology 
A brain tumour may be defined as any intracranial mass created by abnormal and 
uncontrolled cell division, either from the substance of the brain itself or from the 
surrounding meninges or spread from cancers primarily located in other organs also 
referred as metastatic tumours. Metastatic tumours within the CNS occur more frequently 
with increasing age and probably represent the most frequent type of brain tumour in the 
elderly (Smith and Ironside, 2007). Tumours of the central nervous system (CNS) are the 
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second most common form of cancer in children and the sixth commonest in adults. Of 
these, gliomas are the most common CNS tumours in man (Smith and Ironside, 2007). 
Gliomas account for more than 70% of all brain tumours and of these glioblastomas 
(GBMs) are both most frequent and most malignant.  Recent statistics published by the 
Office for National Statistics indicate that of the 245,300 new cases of cancer registered in 
the UK in 2007, 3728 were malignant neoplasms of the brain. It is also reported that 
around 16,000 new cases of brain tumour (both  malignant and benign) are diagnosed each 
year (Office for National Statistics, Cancer Research UK, Brain Tumour Research, 
McKinney 2004). The estimated lifetime risk, calculated in 2009 from these statistics, is 1 
in 133 for men and 1 in 185 for women. Primary brain tumours are commonly located in 
the posterior cranial fossa in children and in the anterior two-thirds of the cerebral 
hemispheres in adults, although they can affect any part of the brain (Pilkington, 2005). 
Primary brain tumours are bimodal in distribution with peaks of incidence at 5-9 years and 
60-75 years (Aldape et al., 2003).  
 
1.3 WHO classification of brain tumours 
The WHO (World Health Organization) classification is the current international standard 
for the nomenclature and diagnosis of gliomas and is subsequently classified into four 
clinical grades, each distinguished by histological characteristics and their presumed cell of 
origin (Louis et al, 2007; Louis, 2008). As the grade number increases, so does the 
malignancy of the tumour, resulting in the most aggressive, malignant glioblastoma 
multiforme (GBM). Although several entities have been described in the 4th edition of the 
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WHO’s classification of tumours of the CNS, only GBMs will be considered in the scope 
of this thesis.  
 
1.4 Gliomas  
Glioma is a generic term used to describe primary brain tumours thought to be derived 
directly from astrocytes, oligodendrocytes or ependymal cells (Sanai et al., 2005) or their 
progenitors. Astrocytomas (WHO grade I to IV) are the most common type of glioma; the 
major associated tumours being pilocytic astrocytomas (Grade I), diffuse astrocytoma 
(Grade II), anaplastic astrocytoma (Grade III) and glioblastoma (Grade IV). 
 
1.4.1 Glioblastoma multiforme 
The most frequent and biologically aggressive glioma is the glioblastoma multiforme 
(GBM) (WHO grade IV) (Perry, 2008). Their histopathological features include nuclear 
atypia, cellular pleomorphism, mitotic activity, vascular thrombosis, microvascular 
proliferation and necrosis. GBMs primarily affect adults, with a peak incidence ranging 
between 45 and 75 years (Neal et al., 2003) and are preferentially located within the 
cerebral hemispheres. Most GBMs arise rapidly de novo, with no previous lesions and are 
termed primary GBM. GBMs that arise from diffuse astrocytoma (grade II) or anaplastic 
astrocytomas (grade III) are termed secondary GBMs. Glioblastoma multiforme (GBM) is 
the most common astrocytic glioma and can arise with no prior neoplastic disease (Behin 
et al., 2003) or can progress from lower grade gliomas (Dai and Holland, 2001). Moreover, 
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the time to progression from diffuse astrocytoma (grade II) to GBM varies considerably 
from less than a year to more than 10 years (Louise et al., 2007). The dismal prognosis for 
glioblastoma patients is due to the invasive nature of the tumour which results in complete 
resection by surgery and, despite progress in radio/chemotherapy, less than half of patients 
survive more than a year. Primary GBMs are genetically characterized by LOH 10q, EFGR 
amplification, p16INK4A deletion which is associated with the retinoblastoma tumour 
suppressor gene (RB1) (Valle- Folgueral et al., 2008) which controls progression through 
G1 to S phase of the cell cycle and finally PTEN mutations (Ohgaki and Kleihues, 2007). 
Despite the short duration of symptoms in many cases of GBM the lesions are often 
surprisingly large at the time of presentation. The lesion is usually unilateral but those in 
the brain stem and corpus callosum can be bilaterally symmetrical. Infiltrative spread is a 
hallmark feature of all diffuse astrocytic tumours, however, GBMs are well known for 
rapid invasion of neighbouring brain structures. A very common feature is extension of the 
tumour through the corpus callosum into the contralateral hemisphere, creating the image 
of a bilateral, symmetrical lesion referred to as the ‘butterfly glioma’ (Louis, 2008). As the 
term glioblastoma ‘multiforme’ suggests, the histopathology of this tumour varies greatly. 
While some lesions show a high degree of cellular and nuclear polymorphism with 
numerous multinucleate giant cells, others are highly cellular (Louis et al., 2007). 
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1.5 Biological features of gliomas  
1.5.1 Proliferation 
A key element in tumour growth and progression is cellular proliferation and the rate of 
cell growth correlates closely with prognosis. Cycle dependent chemotherapy is directed at 
cells which are undergoing mitosis and since mitotic figures are correlated with 
malignancy, it is therefore important to know what percentage of cells is proliferating.  
The mitotic index (MI) is a ratio of cells in mitosis to those which are not. The MI ratio is 
used when grading tumours. A positive correlation has been found between an increase in 
mitotic figures and malignancy. 
Immunohistochemical cell proliferation markers such as proliferating cell nuclear antigen 
(PCNA): a co-factor of DNA polymerase-δ which facilitates and controls DNA replication,  
is involved in the repair of DNA damage, chromatin structure maintenance, chromosome 
segregation and cell-cycle progression (Stoimenov, 2009), Ki-67 antigen: the Ki-67 protein 
is present in G1, S, G2 and M phases of the cell cycle, a fraction of which is also detected 
in quiescent cells (Bullwinkel, 2006) and have been shown to be involved in rRNA 
synthesis in vivo (Rahmanzadeh, 2007), bromodeoxyuridine (BrdU): a thymidine analogue 
which incorporates into newly synthesised DNA and is also a quantitative measure of 
DNA synthesis; have come into general use and the marker-positive cell rate is related to 
histological grading and plays a major role in predicting prognosis (Oda et al., 2005). 
Many of the genetic aberrations found in gliomas, including p53 mutations, bypass the cell 
cycle arrest signals and block the natural apoptotic pathways, resulting in neoplastic cells 
proliferating uncontrollably and continuously (Merzak and Pilkington, 1997). 
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1.5.2 Cellular Heterogeneity 
Clinical management of gliomas currently relies heavily on accurate histopathological 
diagnosis of grade and subtype for provision of appropriate therapy to individual patients 
(Walker et al., 2003).  
The morphological heterogeneity of GBMs has been described since 1865. Genotypically, 
gliomas and cultured glioma cells have been demonstrated to differ within and among 
individuals, according to chromosome number, marker chromosomes and DNA content. 
Phenotypically, cultured glioma cells differ in morphology, growth properties, antigenic 
expression, tumourgenicity in nude mice, and in response to both radiotherapy and 
chemotherapeutic agents. The existence of this inherent complex antigenic heterogeneity 
requires the design of multi-modality therapeutic regimes for each individual patient and 
tumour (Wikstrand et al., 1983). Cultured glioma cells, at least during the early passage 
retain the cellular heterogeneity seen in histological sections taken at the time of surgery 
but this is generally lost with overpassaging (Pilkington, 1992) which emphasizes the need 
to use low passage primary glioma cultures.  
Anaplastic changes in gliomas can be diffuse or it may be possible to distinguish areas 
with low and high grade histological features that may be indicative of progression in some 
parts of the tumour to a higher grade. Many gliomas show mixed histology with features of 
more than one histological subtype present within the same tumour sample or in sample 
obtained from the same patient obtained at different times (Walker et al, 2003). Tumour 
heterogeneity has important morphological, molecular and clinical implications. The 
knowledge of oncogenical alteractions involved in each tumour can be important to 
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correlate the morphological features, the genetic background, the prognosis and the clinical 
response to therapy with anti-cancer agents. Based on the molecular background of the 
tumour there are new cancer gene therapy protocols such as inhibitors of tyrosine kinase 
for the PDGF receptor in gliomas (Lleonart et al., 2000). 
 
1.5.3 Angiogenesis 
Angiogenesis which is the generation of new capillary blood vessels is a characteristic of 
GBM and is an essential component of many physiological and pathological conditions 
including growth and metastasis of primary tumours. Solid tumours require angiogenesis 
to spread larger than a few mm3 and GBMs are known to be one of the most highly 
vascularised of all human tumours (Merzak and Pilkington, 1997). It has however, been 
demonstrated that the rapid growth of GBM results in focal ischaemia and hypoxia, which 
in turn results in angiogenesis mediated by vascular endothelial growth factor (VEGF) 
(Giese et al., 2003). It has been shown that VEGF and PDGF are greatly overexpressed by 
tumour cells in human GBM (Nister et al., 1988, 1991; Westermark et al., 1995). Tumours 
are also able to target and use pre-existing host vessels by induction of angiopoietin-2 
expression by host endothelial cells, thus resulting in the regression of pre-existing vessels, 
tumour necrosis and subsequent onset of hypoxia induced VEGF-mediated angiogenesis 
(Zagzag et al., 2000). 
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1.5.4 Invasion 
Brain tumours may be primary (intrinsic) or secondary (extrinsic), when cells leave a 
primary somatic cancer, intravasate into the bloodstream, arrest at a distant organ and 
eventually develop into gross lesions at the secondary site including the CNS (Mendoza, 
2009).  The brain is in fact a major site for growth of secondary cancers, with 25% of 
malignant tumours showing involvement in the brain (Merzak and Pilkington, 1997). 
Secondary lesions such as these are generally well circumscribed whereas primary brain 
tumours show marked dissemination at the brain/ tumour interface with poor definition of 
the tumour edge. This is due to neoplastic cells migrating several millimeters and 
sometimes even centimeters away from the main tumour mass (Pilkington, 1997 and 
Bolteus et al., 2001). As mentioned previously, there is a preferential invasion of glioma 
cells along white matter tracts, leading for example to the formation of ‘butterfly’ lesions, 
while other gliomas remain confined to the white matter, stopping abruptly at the grey-
white matter junction. Other migratory patterns include preferential growth around neurons 
in the grey matter, perivascular growth and subpial spread (Pilkington, 1994). These 
typical behaviours imply that glioma cells have either a tropism for particular sites or a 
restricted ability to invade in the potential regions between specific cell combinations 
(Louis, 2008). These motile cells termed ‘guerilla’ cells give rise to recurrent tumours, 
following surgical and adjuvant chemo and radiotherapeutic intervention (Pilkington, 
1997). The ability of glioma cells to invade the surrounding brain tissue prevents gliomas 
from complete surgical resection and subsequently successful therapy. It has been 
demonstrated that during this invasive procedure cells transiently arrest from the cell cycle 
(Pilkington, 1994), therefore leaving them refractory to radiotherapy and the response to 
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chemotherapy is likely to be poor (Bolteus et al., 2001). The mechanisms of invasion, 
which include complex, interacting processes between cell adhesion molecules, 
remodeling of the extracellular matrix (ECM) (Rauch, 2004), matrix metalloproteases 
(MMPs), cytosketon elements (Maidment, 1997), gangliosides, growth factors (Finn et al., 
1997) and cytokines (Pilkington, 1997), was first described by Liotta (1986) and is still in 
use to design current models of invasion. Other components which have been associated to 
invasion include Tenascin C, integrins, cadherins, NCAM and Connexin 43 (Demuth and 
Berens, 2004).  
The invading neoplastic glia are protected from cytotoxic drugs by invading into areas of 
the brain protected by an intact blood brain barrier (B-BB). Chemotherapeutic agents can 
infiltrate the main tumour mass where B-BB is compromised but are prevented from 
reaching the invading cell population (Bolteus et al., 2001). Drug delivery to the brain is 
hampered by a major obstacle in the blood brain barrier and many new approaches to 
circumvent this have been suggested. These approaches either serve to increase drug 
delivery of intravascularly administered drugs by manipulating either the drugs or the 
capillary permeability or to increase drug delivery by local administration (Groothuis, 
2000).  Further as stipulated by the ‘go-or-grow hypothesis’ (Bolteus et al. 2001), that is, 
cells either move (invade) or divide, and not both so this transient arrest from the cell cycle 
means that radiotherapy (and some cell cycle specific anti-tumour drugs) will not work on 
migratory cell populations. 
The invasive phenotype of low and high grade tumours is acquired early on in 
tumourgenesis (Louis, 2008). Despite the migratory behaviour and invasiveness of primary 
brain tumours, they rarely metastasize to distant organs (Subramanian, 2002). Pilkington 
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(1997) explained the above statement by suggesting that; 1) time- gliomas are fatal even 
before metastases become detectable; 2) immunity-detection and eradication by patient’s 
own immune system; 3) seed-soil hypothesis- whereby glioma cells are unable to grow in 
different microenvironment; 4) the B-BB may prevent  neoplastic glia from leaving the 
brain and entering the circulatory system and 5) neoplastic glia failing to express the 
required cell adhesion molecules to adhere to other organ endothelium although the fifth 
hypothesis  is the most likely candidate. Martin et al (1995) on the other hand reported that 
CD15; which has been implicated in mediation of adhesion between haemopoietic cells 
and vascular endothelium, may be involved in a similar adhesive role between neoplastic 
cells and endothelia during metastasis; are very low or not expressed on human glioma 
derived cells. 
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Figure 1: Schematic representation of the main actors implicated in invasion of brain tissue 
including urokinase receptor, plasminogen, plasmin, pro-MMPs, PAI-1 (Bellail et al., 2004). 
Note: CD44 and hyaluronan are included as major players in the invasion cascade; these will 
be dealt with in more details in the Introduction (section 1.9) 
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1.5.4.1 The Extracellular matrix  
The ECM affects various functions and processes within the brain. During brain 
development, the ECM modulates the migration of glial and neuronal precursor cells, 
synapse formation and cell proliferation.  
In primary brain tumour, the ECM is aberrantly over-expressed, often giving rise to bizarre 
configurations and undergoes considerable remodeling (Pilkington, 1996). Such changes 
may exert a major influence on brain tumour growth, proliferation and invasion via 
multiple mechanisms (Bellail et al., 2004). 
Neural ECM consists of a variety of collagen superfamily molecules and non-collagenous 
matrix molecules, including hyaluronan, proteoglycans and glycoproteins (Wu, 2005). 
ECM consists primarily of proteoglycans-lecticans and two ECM components: Tenascin 
and hyaluronic acid (Ruoslahti, 1996). These are then directly associated with integrins on 
the cell surface (Viapiano, 2008). ECM is central to the migratory and invasive behaviour 
of glioma cells mediated through integrins associations with ECM (Luwor, 2008). Brain 
tumours have shown that with autocrine and paracrine stimulation, both normal and 
neoplastic cells are capable of producing and secreting ECM components, such as laminin, 
HA and tenascin-C (Bolteus, 2001) to provide a permissive substrate for invasion. HA is 
frequently increased in malignant tumours containing higher amounts than in normal brain 
tissue (Park, 2008) while fibronectin and nonfibrillar collagens (Viapiano, 2006; Viapiano, 
2008) and laminins (Sim, 2009) have both been demonstrated to be produced by neoplastic 
glia. 
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Glial limitans externa Collagen (I, III, IV) 
Fibronectin 
Laminin 
Heparin sulphate 
Vascular basement membrane Collagen (IV, V) 
Laminin 
Heparan sulphate 
Proteoglycans 
Vitronectin 
Fibronectin 
Brain parenchyma Hyaluronic acid 
Dermatan sulphate 
Chrondroitin sulphate 
Hyaluronectin 
Tenascin 
Table 1: Regional distributions of components of extracellular matrix in the brain (Adapted 
from: Rao, 2003) 
 
 
Figure 2: Schematic representation of the heterogeneity and micro regional distribution of 
the various matrix proteins involved in normal brain and glial tumours (Bellail et al., 2004) 
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1.5.4.2 Matrix Metalloproteases 
In vitro and in vivo evidence have shown that the expression of specific extracellular 
matrix proteases stimulates invasive behaviour in gliomas. These include the matrix 
metalloproteinases (MMPs), the urokinase-dependent plasminogen activating cascade and 
cathepsin B (Hughes et al., 1998).  
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases 
(Kahariet al., 1997; Shapiro, 1998; Woessner, 1998) subclassified according to their 
substrate specificity and structures (Westermarck and Kahari, 1999). They include 
membrane-type MMPs, collagenases, gelatinases and stromelysins (Rao, 2003; VanMeter 
et al., 2001). MMPs are produced in cells as pro-enzymes and require proteolytic cleavage 
for activation, for example by serine proteases such as plasmin.  
Increased expression of MMPs has been linked with many malignancies and seems to play 
a pivotal part for tumour invasion and metastasis (Basset et al., 1997; Johnsen et al., 1998).  
It has been hypothesized that MMPs play a crucial role in tumour invasion due to the 
presence of high-level expression of distinct MMPs in invasive malignant tumours 
(Westermarck and Kahari, 1999). Among MMPs, the gelatinases MMP-2 and MMP-9 
have been strongly implicated in glioma invasion and have been observed to be expressed 
in human glioma cell lines and human astrocytoma specimens (Rao, 1993; Sawaya et al., 
1996) with degree of expression correlating with tumour grade (Forsyth et al., 1999). 
There is also a high correlation between the expression of MMP-2 and MMP-9 and the 
ability of glioma cells to invade in vitro (Abe et al., 1994; Uhm et al., 1996). MMPs are 
produced by glioma cells in small quantities ‘on demand’ to remodel/denature the ECM 
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substrate which has previously been produced either constitutively by the brain tissue or by 
the tumour cells themselves in order to provide a base for attachment and permissive 
substrate for invasion. The sequence of events involves: 
a. Lamelipod (invadopod) extension 
b. CAM expression 
c. ECM secretion (in absence of brain derived ECM, e.g, HA) 
d. Adhesion/purchase 
e. Contractile force (cytoskeletal re-organisation) 
f. Progressive movement 
g. Denaturing of ECM by e.g MMPs to break bond 
h. Repeat of a-g. 
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Figure 3: Structure of human matrix metalloproteinases (Adapted from: Kahari et al., 1997) 
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1.5.4.3 Adhesion molecules 
Cell adhesion molecules are families of cell surface glycoproteins with large extracellular 
domains, a membrane spanning region and an intracellular and cytoplasmic functional 
domain (Goodison et al., 1999). They facilitate strong bonding to a specific ligand through 
a complex process involving the cell ‘sensing’ the extracellular environment and sending 
out information to adjacent cells. Cell adhesion molecules (CAMs) such as integrins, 
cadherins and immunoglobulin proteins (Sloan et al., 2004) are involved in cell motility in 
response to soluble ECM proteins and migration, differentiation, cell signaling and gene 
transcription (Cheney, 1998). CAM sits at the top of many signaling cascades that regulate 
actin and microtubule dynamics through Rho GTPases (Bogenrieder and Herlyn, 2003). 
The ‘key’ CAMs in glioma invasion are: CD44 and NCAM (Neural Cell Adhesion 
Molecule). 
 
1.5.4.4 Integrins 
Integrins are key molecules on the cell surface which facilitate ECM/CAMs interaction and 
binding (Uhm et al., 1999). They are expressed as cell surface heterodimers consisting of α 
and β subunits which are non-covalently linked. Currently, 18 different α and 8 different β 
subunits have been described (Milner and Campbell, 2002). Their mediating role in 
adhesive events during malignant transformation, tumour growth and progression, invasion 
and metastasis occurs through provision of a physical transmembrane link between the 
ECM and the underlying cytoskeletal elements, which results in transduction of 
bidirectional signals across the cell membrane. 
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Some integrins bind only one specific ligand while others bind several different ligands 
and equally, some ECM ligand also bind to multiple integrin (Van der Flier and 
Sonnenberg, 2001). 
β1 integrin is a 130 kDa transmembrane glycoprotein made up of alpha subunits and form 
non-covalent complexes with various integrin alpha subunits to form the receptors that 
bind to specific extracellular matrix proteins and is centrally involved in invasion. β1 
integrin is probably the most common expressed subunit in glioma (Rooprai, 1999).  
αv integrin in brain tumours has been linked with glioma invasion either by the fibronectin 
ligand αvβ1 or αvβ3 receptor that interacts with vitronectin, tenascin, osteopontin, von 
willebrand factor or thrombospondin and facilitates extracellular matrix cell adhesion 
(Bellail et al., 2004). 
The clustering of integrins on a cell surface leads to the formation of focal contacts. It has 
also been reported that the interactions between integrins and the extracellular matrix 
trigger signal transduction pathways and plays a role in regulating gene expression. 
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Figure 4: Schematic representation of the integrin subunits and their ligands in glioma 
invasion (grey shade region) versus normal. Integrins are expressed as heterodimers and fall 
into three main groups: β1, β3 and αv (Bellail et al., 2004). 
 
1.6 Proliferation and Invasion 
The notion that neoplastic glial cells transiently arrest from the cell cycle during invasion 
resulted in the theory that glioma cells either ‘grow’ (proliferate) or ‘go’ (invade), with 
these events being mutually exclusive (Bolteus et al., 2001). Indeed, many anti-invasion 
strategies have shown that inhibition of invasion stimulates cell proliferation (Fedotov and 
Iomin, 2007) and vice versa. Behaviourally, gliomas can be viewed as consisting of two 
discrete sub-populations of cells, the proliferative cells at the tumour core and the more 
peripheral cells invading into the brain parenchyma, although these two ‘populations’ are 
functionally reversible by modification of cell surface or other molecules required for the 
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divergent processes of invasion and proliferation. Therefore, the gene expression profile of 
the tumour core may not depict the genetic profile of the invasive edge. Demuth and 
Berens (2004) used laser capture microdissection (LCM) of frozen sections from human 
biopsy samples to isolate cells from the tumour core and the invasive edge and performed 
cDNA microarrays comparing genes in both subpopulations. This led to the identification 
of genes differentially expressed in invasive glioma cells and included over expression of 
P311, Death- associated- protein 3 (DAP3), FN14 and P13-K (Demuth and Berens, 2004). 
Thier et al (2000) evaluated the relationship of proliferation rates using the BrdU labeling 
index and MMP activity in neuroectodermal tumour cell lines. The expression of some 
MMPs such as MMP2, MMP9 & MMP14 (MT-MMP) has been found to positively 
correlate with the degree of malignancy in gliomas. The cell lines with high MMP-2 
expression levels recorded low levels of proliferative activity and vice versa. The 
conclusion was that proliferation was inversely correlated to MMP-2 expression in the 
glioma cells evaluated (Their et al., 2000). Research emphasizes that suppression of 
migration might enhance cell proliferation leading to enhanced tumour cell death by either 
radiotherapy or chemotherapy.  
 
1.7 Treatment modalities for gliomas 
Depending on the type of tumour and its location, the likely course of events will be 
surgery, radiotherapy (RT) and chemotherapy (CT); however, despite aggressive therapy 
including combined surgery, radiotherapy and chemotherapy, GBM recurs within 6-12 
months (Neider et al., 2000). Relapse occurs in approximately 80% of cases usually within 
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2-3cm of the margin of the original lesion (Neider et al., 2000). Currently, the standard 
treatment modality for high grade malignant glioma is surgical resection followed by focal 
radiotherapy however; the use of adjuvant chemotherapy at the time of surgery and 
radiotherapy is widely used (Brandes, 2003). 
 
1.7.1 Surgery 
Surgical intervention is the most common form of treatment for glioma and there are 
several indications for the use of surgery which include reduction of tumour burden, 
alleviation of mass effect, control of seizures, reversal of neurological deficit, confirmation 
of histological diagnosis, diversion of cerebrospinal fluid (CSF) by shunting procedures 
and the introduction of local chemotherapeutic agents (Newton and Jolesz, 2008). Tumours 
can either be completely or partially resected or biopsied. Even partial resections are 
beneficial to the patient (Castro et al., 2003). When surgical resection is indicated the aim 
is to remove as much as possible. However; GBM are difficult to resect because of lack of 
a defined tumour edge, as the tumour often extends into normal brain tissue or may be 
localized near the critical brain areas. In this respect, radiotherapy is the choice of 
supplementary therapy to target residual tumour (Brandes, 2003). Recent advances in 
neurosurgical techniques offer new approaches to tumour removal such as frame-based and 
frameless stereotactic biopsy, pre-operative functional magnetic resonance imaging (MRI) 
and intra-operative cortical mapping, neuronavigation, tumour resection in ‘awake’ 
patients and the use of intra-operative MRI (Matz et al., 1999 and Nimsky et al., 2001). 
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1.7.2 Radiotherapy (RT) 
Following surgical resection RT can be used to kill residual tumour cells and several 
clinical trials have shown this to increase survival in patients with high-grade gliomas 
(Little and Friedman, 2004). Nieder and collegues (2000) indicated that the survival of 
patients with various RT techniques is broadly similar, however, considerable toxicity is 
associated with radiosurgery and brachytherapy therefore, to minimise brain damage 
caused by high dosage, hyper fractionated external beam RT can be used. This technique 
delivers more frequent fractions of a smaller dose over a smaller region of the brain. 
Stereotactic radiosurgery has been developed, allowing delivery of more precise, higher 
doses RT to a small section of the brain. Brachytherapy can be used if the tumour is well-
defined, surgically accessible and <5cm in diameter. This method uses radioactive pellets 
implanted within the tumour to kill cancer cells and minimise the exposure of normal brain 
tissue (Nieder et al., 2000). 
 
1.7.3 Chemotherapy  
Post-operative chemotherapy has been correlated with an increase in survival of patients 
with high grade glioma (Nieder, 2009). Chemotherapy of brain tumours is not curative and 
the goals of treatment are mainly to control tumour growth and maintain good quality of 
life for patient for as long as possible. Cytotoxic drugs used in chemotherapy are 
developed to kill neoplastic cells or leave them radiosensitive while preserving normal 
cells. The intact B-BB prevents access to the tumour whereas a disrupted B-BB still 
provides limited protection for the tumour from chemotherapy therefore various strategies 
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are available such as intra-arterial, intrathecal and intratumoural as well as disruption of B-
BB. The most common chemotherapy drugs are the nitrosoureas. Other agents also used 
include platinum-based drugs, procarbazine, viscristine- a vinka alkaloid which attacks the 
nuclear spindle and naturally occurring compounds (Castro et al., 2003). Temozolamide 
(TMZ), an alkylating agent is currently the agent of choice for the treatment for 
glioblastoma (Stupp et al., 2001) and was introduced for general use following an 
exhaustible major evaluation and re-evaluation by the National Institute for National 
Excellence (NICE). 
The main disadvantage with chemotherapy is that not all tumours are responsive to the 
drugs used and there may be serious adverse effects. Stewart (2002) assessed the effects of 
systemic chemotherapy and/or RT on survival and recurrence in adults with high-grade 
glioma reported a small but clear improvement in survival. One trial has further reported 
that median survival of patients receiving carmustine polymers (Gliadel wafers) was 31 
weeks compared with 23 weeks for patients receiving placebo polymers (Brem et al., 
1995). 
 
1.7.4 Prognostic Indication and therapeutic response 
Another group of therapies include the alkylating agents such as the Procarbazine-
Lomustine (CCNU)-Vincristine (PCV) regimen (Oncovin®). The more recently 
discovered Temozolomide (Temodal®) is also an alkylating agent, its mode of action 
occurs through its ability to methylate DNA at the N-7 and O-6 positions on guanine 
residues which subsequently blocks the cell cycle at the G2-M boundary and triggers 
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apoptosis (Friedman 2000). However, some degree of resistance to the action of 
temozolomide on gliomas has been reported and it is thought that the tumour cells 
expressing the enzyme MGMT exhibit a poor response to temozolomide treatment and 
such CpG methylation of the MGMT promoter (dictating MGMT expression) is a 
predictive factor of treatment response. Additionally, LOH at 1p 19q in 
oligodendrogliomas appears to correlate to chemosensitivity and an improved prognosis. 
Other cell cycle disrupting agents include carboplatin and irinotecan (Simpson and 
Galanis, 2006). 
Agents that act on the mitochondria to induce tumour cell death are few and far between, 
but the tricyclic Clomipramine (Anafranil®)-originally licensed to treat depression-is one 
such agent. Its ability to cross the B-BB and target the mitochondria of neoplastic cells but 
not healthy tissue and without inducing DNA damage indicates its potential as a 
therapeutic agent in the treatment of glioma but as yet no clinical trials have been carried 
out and the drug is not generally available to patients. 
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1.8 Future therapeutic strategies 
Standard methods of cancer therapy offer relatively no specificity to malignant lesions and 
frequently cause serious adverse effects. The revolution in molecular medicine has allowed 
the development of novel therapeutic modalities, in which cancer-specific changes can be 
utilized for targeted therapies. The alternative therapies should aim to combat local 
invasion of tumour cells and develop cytotoxic drugs that can cross the blood brain barrier 
and be effective against both dividing and migrating cells. Potential approaches include 
gene therapy, specific molecular targeting, clinical immunotherapy, anti-invasion, anti- 
angiogenesis, pro-apoptotic strategies and mitochondrial targeting. Molecular targeting 
therapies hold promise of providing new cancer treatments that are more effective and less 
toxic than traditional cytotoxic agents.  
 
1.9 CD44 
CD44, originally known as the lymphocyte homing receptor, is a multistructural and 
multifunctional cell adhesion glycoprotein (Naot et al., 1997). It has been previously 
allocated the names Hermes-1, lymphocyte homing receptor, Pgp-1 and extracellular 
matrix receptor III (Picker et al., 1989; Jalkanen et al., 1986; Omary et al., 1988 and 
Gallatin et al., 1989). The human CD44 gene is located at the chromosomal locus 11p13 
and exists as two isoforms. The most abundant standard isoform of human CD44 protein 
(CD44s or CD44H) contains 363 amino acids and has a molecular weight of ~ 80kDa and 
the largest possible protein, containing peptides from all variant exons (CD44v or CD44E) 
is 150kDa (Aruffo et al., 1990; Miyake et al., 1990; Stamenkovic et al., 1991 and 
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Akiyama, 2001). The standard isoform (CD44s) consists of exons 1-5 and 16-20. The 10 
variable exons 6-15 (v1-10) (Hofmann et al., 1991; Tolg et al., 1993; Screaton et al., 1992) 
are designated CD44v.  
 
 
Figure 5: Schematic diagram of the structure of the CD44 gene. The standard exons (s1-10) 
encode the ubiquitously expressed standard protein isoform, CD44s. combinations of the 
variant exons (v1-10) can be alternatively spliced between s5 and s6 to encode variant protein 
isoforms, CD44v. exon 6 (v1) of the human gene contains a stop codon and is not normally 
included in human mRNA (Goodison et al., 1999). 
 
The protein consists of three regions, a 72 amino acid C-terminal cytoplasmic domain, a 21 
amino acid transmembrane domain and a 270 amino acid extracellular domain. The 
cytoplasmic region is encoded by part of exon 18 and by exons 19 and 20 (Goldstein et al., 
1990).  
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Figure 6: CD44 protein structure, the standard isoform binds its principal ligand, hyaluronic 
acid at the N-terminal, distal extracellular matrix. The molecule interacts with the 
cytoskeleton through the binding of ankyrin and the ERM family (ezrin, radixin moesin) to 
the cytoplasmic domain (Goodison et al., 1999) 
 
 
1.9.1 Expression of CD44  
Most mammalian cells predominantly express the CD44s isoform but some epithelial cells 
also express CD44v/CD44E (Iida and Bourguignon, 1995). The expression of CD44 
isoforms containing combinations of the other variant exons (CD44v) is relatively 
unknown in normal tissues but it is indicative of invasive and metastatic propensity of 
cancer cells (Bellail et al., 2004). However, CD44v has been found in haemopoietic cells 
(Stauder et al., 1995), particularly in peripheral blood mononuclear cells (Salles et al., 
1993) and in reactive lymph node cells (Arch et al., 1992). The expression of CD44v6 has 
been seen in the ducts of breast (Terpe et al., 1994) and pancreas (Gansauge et al., 1995; 
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Hong et al., 1995) and CD44v4 is expressed in normal urothelium (Southgate et al., 1995). 
CD44 is expressed in normal astrocytes (Okamoto et al., 2002) although the expression is 
considerably less in comparison with neoplastic astrocytes (Pilkington et al., 1993). 
Certain cell types, however, do not express any CD44, including hepatocytes, pancreatic 
acinar cells and cells of the tubules of the kidney and pancreas (Mackay et al., 1994). 
 
1.9.2 Function of CD44  
CD44 is centrally involved in a wide spectrum of activities notably lymphocyte homing 
and activation, cell-matrix interactions, cell migration, tumour invasion and metastasis 
(Okamoto et al., 2002) and specifically as a receptor for hyaluronic acid (HA) (Gunthert, 
1993). Indeed, the multiple functions reported for the CD44 family of proteins have largely 
centered around the binding of HA (Culty et al., 1992). The various functions reported for 
CD44 are, in part, also possible by the alternative splicing of the pre-mRNA and the fine 
tuning of ligand binding (Tolg et al., 1993). 
 
1.9.2.1 Role in cell adhesion 
The main role of CD44s protein is in the maintenance of three dimensional organ/tissue 
structure. Upregulation of CD44 and HA production facilitates development of a structural 
scaffold during epithelial growth and repair (Alho et al., 1989; Jain et al., 1996). 
Moreover, a high amount of HA has been found in angiogenesis (Trochon et al., 1996), 
wound healing (Jain et al., 1996) and embryonic cell migration (Sherman et al., 1996; 
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Wainwright et al., 1996). HA serves as a ligand support for CD44 mediated cell movement 
and mediates the aggregation of cells by multivalent HA binding by CD44 on adjacent 
cells or by CD44/CD44 binding via attached glycosylation moieties (Cooper and 
Dougherty, 1995).  
 
1.9.2.2 Role in neoplasia 
The expression of multiple CD44 isoforms and the resulting HA binding profile can 
influence tumour growth and development. Initial studies showed that tumour tissues 
contained a number of unusual CD44 transcripts when compared to those in normal tissues 
(Stamenkovic et al., 1989; Stamenkovic et al., 1991). Furthermore, it has been 
demonstrated that tumour cell lines with high level of CD44 proteins were able to form 
more aggressive tumours in animal experiments (Birch et al., 1991; Sy et al., 1991). 
Gunthert (1991) demonstrated in an athymic mouse model that by transfecting plasmids 
expressing CD44s or CD44v isoforms into non-metastatic, rat pancreatic carcinoma cells,  
the CD44s gene had no effect in upregulation of metastasis while CD44v expression 
conveyed metastatic competence to these cells. The ability of the CD44v expressing cells 
to metastasize was not dependant on HA binding; this was confirmed as a CD44 exon v6 
specific antibody that blocked metastasis formation in this system (Seiter et al., 1993) did 
not interfere with HA binding (Sleeman et al., 1996). There is also evidence for a 
correlation between raised CD44 expression and metastatic capability in both cultured 
human melanoma (Birch et al., 1991) and lymphoma cell lines (Sy et al., 1991). These 
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observations therefore, suggest that cell surface CD44 function promotes tumour cell 
survival in invaded tissues.  
 
1.9.3  CD44 in brain tumours 
Data from extensive studies have shown that CD44 is expressed in both neoplastic and 
reactive astrocytes but over-expressed in neoplastic cells where it aids glioma cell adhesion 
and invasion (Okamoto et al., 2002). In glioblastomas, several species of CD44 mRNA are 
expressed and encode standard CD44 (Kuppner et al., 1992; Pilkington et al., 1993). 
Merzak and colleagues (1994) showed that CD44 is directly involved in human glioma cell 
invasion, through interaction with extracellular matrix (ECM) components. However, to 
date, CD44 splice variants occur in brain metastases but not primary brain tumours thus 
suggesting a specific role of CD44v in metastasis (Li et al., 1993). On the other hand, since 
CD44s has been shown to mediate attachment to a variety of ECM components, including 
hyaluronate (Pilkington, 1994; Asher et al., 1992), CD44-hyaluronate binding would 
facilitate the migration of cells through the brain ECM. The notion that CD44 being 
essential for invasion is supported by both in vitro and in vivo investigations including 
antisense inhibition of CD44 in vitro and the observation that intracranial injection of 
glioma cells with low CD44 expression levels into nude mice provided localized well-
circumscribed neoplasms (Okada et al., 1996). Furthermore, monoclonal antibodies 
directed against CD44 decreased intracerebral invasion of glioma cells both in vivo and 
through in vitro matrigel matrices (Gunia et al., 1999). Moreover, a proteolytic cleavage of 
the extracellular portion of CD44 has been shown to occur in gliomas but not in normal 
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brain (Okamoto et al., 1999). In several tumour cell lines, including glioma, this cleavage 
led to the release of a soluble fragment in the medium and also to a membrane-bound 
cleavage product (Okamoto et al., 1999). In vitro, it has been shown that the soluble and 
the membrane-bound fragments of CD44 promote tumour cell migration (Kajita et al., 
2001; Okamoto et al., 1999).  
 
1.9.4 CD44 and interaction with Hyaluronic acid (HA) 
Depending upon tissue type, a range of extracellular adhesive proteins and their receptors 
on the cell surface are important factors for cell attachment (Bignami et al., 1993). 
Hyaluronic acid and its receptor (CD44) are key players for this role in the brain. HA is 
one of the constituents of extracellular matrix and is a 85 kDa glycosaminoglycan (Misra 
et al., 2009) present in almost tissues of vertebrates and regulates cellular events such as 
cell proliferation and locomotion that are required for a variety of biological processes, 
including tumourigenesis (Cao et al., 2006). Tumours often contain high levels of HA 
which correlates with invasion and increased malignancy in some neoplasms (Merzak et 
al., 1997; Stamenkovic, 1991). HA is particularly over-expressed to approximately four- 
fold in primary brain tumours (Delpech et al., 1993). HA has been shown to facilitate 
primary brain tumour invasion in vivo and migration in vitro through its two cellular 
receptors, CD44 and RHAMM (Receptor for Hyaluronic Acid-Mediated Motility). 
Antibodies directed against these receptors have been shown to inhibit invasion and 
migration (Akiyama et al., 2001).  
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The exact mechanism by which CD44 and HA interact to mediate migration and invasion 
are still under investigation however aggregates of CD44 expression at the interface of 
normal brain and glioma spheroids appear to link cell membrane surfaces to HA (Merzak 
& Pilkington, 1997).  As part of its diverse cell interactions, HA plays a role in cell 
detachment from supporting matrices such as ECM. This enables cells to detach, migrate 
and divide more easily. Studies in animal models demonstrate the injection of reagents that 
disturb CD44-ligand interaction, which subsequently inhibit local tumour invasion and 
metastatic spread (Stern et al., 2001). Moreover, HA takes on water of hydration, swells 
and pushes aside the brain tissue to allow CD44/HA mediated tumour cell invasion (Stern 
et al., 2001). Then, subsequently the tumour cells produce and secrete hyaluronidase which 
breaks down HA. The breakdown products are angiogenic, which induce blood vessels to 
recruit to the tumour.  
 
1.10  CD155 
Poliovirus is a small iscosahedral RNA virus which belongs to the picornavirus family. It 
was first recognised to mediate binding, poliovirus to host cells, which causes symptoms 
such as flaccid paralysis characteristic in poliomyelitis (Sloan et al., 2004; Sloan et al., 
2005). The restricted tropism of poliovirus is poorly understood. In addition to the 
restricted cell and tissue tropism, poliovirus only infects primates and primate cell cultures. 
Other mammalian species remain unaffected (Ren et al., 1990). 
The isolation of poliovirus in 1908 and subsequent discovery of the human poliovirus 
receptor (PVR), as the cellular docking molecule for poliovirus, was followed by the 
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development of a transgenic mouse expressing the human poliovirus receptor as an animal 
model for poliomyelitis such as mice, when infected with poliovirus, developed a 
neurological syndrome histopathologically and clinically identical to primate poliomyelitis 
(Koike et al., 1991). 
The poliovirus receptor (PVR) has now been classified as CD155 (Mendelsohn et al., 
1989). CD155 or human poliovirus receptor (PVR) is a highly glycosylated ~70kDa type 
Ia transmembrane cell surface glycoprotein molecule that is part of an immunoglobulin 
superfamily of CAMs (Merill et al., 2004; Bottino et al., 2003). Its extracellular region 
contains three immunoglobulin-like domains: an outermost V-like domain followed by two 
C2-like domains (Mendelsohn et al., 1989). The CD155 gene belongs to a subgroup of the 
immunoglobulin superfamily sharing the general extracellular structure V-C2-C2. CD155 
is expressed in four isoforms: hPVRα and hPVRδ are membrane-bound variants that differ 
only in the sequence of the cell-internal C-terminal domain, while hPVRβ and hPVRγ are 
secreted isoforms lacking the transmembrane domain (Koike et al., 1990; Wimmer et al., 
1993). hPVRα and hPVRδ are type Ia single-pass transmembrane glycoproteins with 
apparent molecular weight of >80 kDa, whereas the core polypeptides are 42.5 and 40 kDa 
respectively. Binding of poliovirus occurs at the V-domain of the polypeptide (Bernhardt 
et al., 1994). 
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Figure 7: CD155 protein structure. The overall domain arrangement of CD155 is indicated 
on top. The lengths of individual domains subdivided by the cysteine disulfide bonds 
characteristic for the IG-like domains are indicated by numbers (Gromeier et al., 2000) 
 
 
Figure 8: Ribbon diagram of CD155 domain. Residues in the virus-receptor binding 
interfaces are shown in coloured spheres (He et al., 2003). 
 
 
1.10.1 Expression of CD155 
Although previous studies have shown that CD155 is widely distributed throughout human 
tissues, its level of expression is strictly regulated (Freistadt, 1994; Solecki et al., 2000) 
and it is found only in primates (Aoki et al., 1994; Koike et al., 1992). CD155 is not highly 
expressed in adult human brain (Tokuyuki, 2008) but ubiquitous CD155 expression is 
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confirmed in sites such as the human spinal cord, motor neurons, leukocytes and many 
human tissues such as kidney, ileum, liver, lung and placenta (Sloan et al., 2004; Bernhardt 
et al., 1994). However, CD155 is localised in ECM and at cell-cell junctions but tends to 
show particularly low levels of expression thus making it difficult to determine exact levels 
of expression in specified sites (Merrill et al., 2004). 
 
1.10.2 Function of CD155 
Although the physiological function for CD155 is unknown, the protein was shown to bind 
specifically to the extracellular matrix vitonectin (Lange et al., 2001) and thus classified as 
a cell adhesion molecule binding protein. Research currently suggests it may play a role as 
a regulator of cancer invasiveness and glioma migration through its ability to inhibit cell 
adhesion and enhance cell migration (Sloan et al., 2005). Other known molecular functions 
of CD155 are: protein binding, receptor activity and viral receptor activity. William and 
Barclay (1988) highlighted that most of the proteins in the Ig superfamily including CD155 
are involved in cell-cell interaction during normal or pathological processes such as 
inflammation, tumourigenesis and cancer metastasis. 
 
1.10.3 CD155 in neoplasia 
The first suggestions of a link between CD155 and cancer were centered around the use of 
poliovirus to infect and destroy human tumour cells. Such neoplastic cells obtained from 
surgical resections were susceptible to poliovirus while non-malignant cells resisted the 
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poliovirus. Thus, it is assumed that susceptibility to poliovirus was based on 
overexpression of CD155 following malignant transformation. The link of CD155 with 
cancer is further evident from studies of the expression of CD155 during embryonic 
development. Like many of its fellow members of the immunoglobulin superfamily, 
CD155 appears to be expressed during embryonic development. Frequently, 
immunoglobulin superfamily molecules that are expressed in a developmental manner 
have been associated with malignancy (Walsh et al., 1997). More recently CD155 has been 
identified as a tumour antigen as its expression is up-regulated in neuroectodermal cancers, 
such as glioblastoma multiforme, medulloblastoma and colorectal carcinoma (Vestweber, 
2002 and Weber, 2003). 
 
1.10.4 CD155 in brain tumours 
It has been reported that CD155 is over-expressed in malignant gliomas (Gromeier et al., 
2000) and that increased levels of CD155 are expressed on neoplastic cells from primary 
brain tumours of several types including GBM (Sloan et al., 2004). CD155 expression 
levels in tumour tissues corresponded to those in primary tissue cultures derived from the 
tumours. Furthermore, CD155 expression in primary glioma explants cultures was equal to 
that found in established glioma cell lines used in preclinical evaluations of oncolytic 
poliovirus recombinants (Merrill et al., 2004). Further studies carried out by Sloan and 
collegues (2004) have revealed that CD155/PVR was highly expressed in both U87 human 
glioma cells and primary glioblastoma tumour tissue.  
 
38 
 
1.10.5 CD155 and ECM interactions 
Although the exact mechanism by which CD155 controls glioma migration is still unclear, 
it is postulated that it is recruited to the leading edge of migrating tumour cells and co-
localises with integrins and actin, which are involved with the processes of motility and 
cell-substrate adhesion (Bernhardt et al., 1994). More specifically, CD155 binds to 
vitronectin, which is a major serum protein, abundant in high grade gliomas and an 
important constituent of the ECM (Lange et al, 2001; Ohnishi et al., 2007). Vitronectin has 
further been reported to promote glioma cell survival and invasion (Gladson et al., 1995; 
Uhm et al., 1999). CD155 has been demonstrated to bind to vitronectin and additionally 
co-localise with specific integrins in cancer cells (Sloan et al., 2005). It is thought that 
control of invasion by CD155 maybe substrate-dependent and that by decreasing the 
stability of focal adhesions at the cell-substrate interface, neoplastic cells become less 
adherent and more motile (Sloan et al., 2005). This proposed interaction establishes an 
additional link between CAMs and ECM in glioma cells (Lange et al., 2001). Further 
evidence of up-regulation of CD155 expression in glioma cells suggests a potential 
mechanism which reflects its invasive phenotype which is necessary for cancer progression 
(Bernhardt et al., 1994; Ohnishi et al., 2007). 
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1.11 Association between CD44 and CD155  
To date, Freistadt and Eberle (1997) have provided promising evidence that there is a 
physical association between CD155 and CD44 on the cell membrane of blood monocytes. 
They demonstrated that anti-CD44 monoclonal antibody (mAb) inhibited the binding of 
anti-CD155 mAb. Similarly, Shepley and Racaniello (1994) demonstrated that anti-CD44 
mAb hindered the binding of poliovirus to CD155 due to its steric position. These studies 
reflect a close physical apposition between CD155 and CD44. It has been suggested that 
CD44 may act as a co-receptor for cellular uptake of poliovirus; however the localisation 
of CD44 in human tissues does not correlate with poliovirus susceptibility (Shepley and 
Racaniello, 1994). However, such interaction between CD44/CD155 and its implications 
have yet to be researched with respect to brain tumours. In particular work on the role of 
CD155 in brain tumour is still in its infancy and its possible role as a therapeutic target for 
invading tumour cell populations in primary brain tumours remains to be explored. 
However, if a similar juxtaposition of CD44 and CD155 as has been reported on 
monocytes could be observed on brain tumour cells, this might further indicate that 
CD44/CD155 plays an interactive role, possibly in conjunction with certain integrin 
subunits at the tumour cell surface, resulting in mediation of brain tumour invasion via the 
underlying cytoskeleton. An intimate knowledge of interactive process underlying 
invasiveness, including those which include CD44 or CD155 may prove valuable in the 
development of new therapeutic strategies.  
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1.12 F-Actin 
Actin, one of the major components of the cytoskeleton is a structural, roughly 42 kDa 
conserved protein in eukaryotic cells (Rao et al., 1990). Its main importance is in 
regulation of cell shape, motility, secretion, intracellular transport and cell division 
(Wessells et al., 1971 and Pollard et al., 1986). Actin exists in the cytoplasm as either G-
actin monomers or F-actin filaments. G-actin (globular actin) with bound ATP can 
polymerise to form F-Actin (Filamentous Actin) (Rao et al., 1991). Actin levels may 
reflect cancer-related changes at molecular level through several mechanisms including a 
point mutation in the actin gene and altered regulation of F-actin assembly (Hunter, 1984; 
Magargal, 1986; Akiyama et al., 1988; Holme et al., 1986 and Marchisio et al., 1987). 
 
1.13 Signal transduction pathways 
1.13.1 Rho GTPases 
Cells receive various chemical (cytokines and growth factors) and physical (mechanical 
stress or adhesion to extracellular matrix) stimuli that influence cell function by affecting 
intracellular signaling pathways (Bushsbaum, 2007). These stimuli usually involve cell 
surface receptors or other molecules that function through activation of the Rho family of 
small GTPases. Rho GTPases are members of the Ras superfamily of small GTPases that 
play a pivotal role in controlling multiple cellular processes, including integrin engagement 
(Ridley et al., 1992; Hall, 1998; Nobes et al., 1995; Del Pozo et al., 2002) and assembly 
and organisation of the actin cytoskeleton (Symons et al., 2009). 
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To date more than 20 members of the Rho GTPases family have been identified 
(Wennberg and Der, 2005) including Rho (RhoA, RhoB, RhoC), Rac (Rac1, Rac2, Rac3) 
and Cdc42 (cell division cycle 42) (Bishop & Hall, 2000; Ridley, 2001; Boettner and Van 
Aelst, 2002; Ridley et al., 2003; Burridge & Wennerberg, 2004; Jaffe & Hall, 2005) 
(Figure 9). RhoA, RhoB and RhoC are Ras homolog gene family members A, B and C 
respectively. Rac1, Rac2 and Rac3 are Ras-related C3 botulinium toxin substrate 1, 2 and 3 
respectively. 
 
Figure 9: The RHO-protein family. The RHO proteins can be subdivided on the basis of 
functional, biochemical and sequence data. The subgroups include proteins that are most 
similar to RhoA, those that are most similar to RAC1 and CDC42, and those that lack 
GTPase activity. The RND proteins and RHOH have been grouped together because of their 
predicted lack of GTPase activity (Sahai and Marshall, 2002). 
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Rho GTPases proteins act as molecular switches that cycle between inactive GDP-bound 
and an active GTP-bound state (Figure 10). In the GTP-bound active state, Rho GTPases 
interact with target proteins known as effectors to induce a cellular response until GTP 
hydrolysis returns them to the GDP-bound inactive state. The interconversion between the 
GDP-bound to the GTP-bound state is mediated by a large family of guanine-exchange 
factors (GEFs) that increase GDP/GTP exchange rates and GTPase-activating proteins 
(GAPs) that elevate the intrinsic GTPase activity of Rho GTPases (Hall et al., 2005).  
 
Figure 10: Model of RHO-protein regulation. RHO proteins can bind either to GTP or GDP. 
When bound to GDP, they can be sequestered in the cytoplasm by RHO-GDP dissociation 
inhibitors. The exchange of GDP to GTP is promoted by RHO by guanine nucleotide 
exchange factors and is often associated with translocation of RHO proteins to proteins cell 
membranes. GTP-bound RHO proteins interact with a range of effector proteins and 
modulate their ability to regulate cell behaviour. Most RHO proteins have an intrinsic ability 
to hydrolyse GTP to GDP and inorganic phosphate (P), which can be promoted by RHO- 
GTPase-activating proteins (Sahai and Marshall, 2002). 
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1.13.2 Rho GTPases in invasion 
Invasion is a complex process that relies on the spatial and temporal organization of actin 
dynamics, adhesion and protease activity. Regulation of the actin cytoskeleton, formation 
of membrane projections and assembly of specialized adhesion complexes in glioma 
invasion may all be mediated through Rho family members (Banyard et al., 2000). Indeed, 
Rho family proteins have distinct roles in regulating the actin cytoskeleton and the 
formation and regulation of actin-rich protrusive structures that are actin-containing 
membrane structures that mediate different aspects of cell motility and adhesion (Hotchin 
and Hall, 1995).  Rac1 is known to regulate actin polymerisation at the cell periphery to 
produce the sheet-like lamellipodia and the ruffles. Cdc42 promotes actin filament 
assembly to induce the formation of thin finger-like filopodia. Rho is required for the 
formation of contractile actin-myosin filaments, also known as stress fibres, and regulates 
the formation and maintenance of focal adhesions (Ridley et al., 1992; Hall et al., 2005). 
Normally low levels of Rac1 induce lamellipodia/ruffle formation at the two extremities of 
the main axis whereas higher levels of Rac1 induce lamellipodia/ruffles around the whole 
perimeter of the cell (Pankov et al., 2005). Rac is also involved in cell spreading and 
integrin-dependent adhesion to the extracellular-matrix (D’Souza-Schorey et al., 1998). 
Temporal and spatial controlled Rac1 activation is also important in different phases of 
cell-cell adhesion (Ehrlich et al., 2002; Cascone et al., 2003). 
It is most probable that Rho proteins play a role in the invasive phenotype of tumour cells 
(Figure 11) knowing that they are involved in the regulation of cell motility in normal cells 
and their peculiar regulation in tumour cells. While many in vitro studies show that Rho 
proteins are involved in cell motility; precisely how Rho proteins promote 
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invasion/metastasis remains to be elucidated. RhoC and its effector ROCK have however, 
clearly been shown to be implicated in in vivo models of tumour-cell dissemination (Clark 
et al., 2000; Itoh et al., 1999; Murata et al., 2001; Somiyo et al., 2000). 
It is postulated that the mechanism of invasion by the Rho proteins is as follows: Rho 
proteins are involved in the loss of epithelial polarity and are thought to be determinant in 
the epithelial-mesenchymal transition that is occasionally observed in aggressive tumours. 
Normal epithelial sheets are characterised by cell polarity and a well-organised array of 
specialized cell-cell junctions such as adherens and tight junctions. High levels of 
RND3/RhoE, which antogonises RhoA function (Guasch et al., 1998; Nobes et al., 1998) 
can promote a loss of polarity and multilayering of epithelial cells (Hansen et al., 2000). 
On the other hand, inhibition of Rac1 leads to a loss in polarity resulting in the non-
deposition of laminin asymmetrically (O’Brien et al., 2001). Data collected by Kim (2000) 
showed the association of Rac1 with the mammalian orthologues of the Caenorhabditis 
elegans cell-polarity genes par3 and par6 might also be involved in controlling epithelial-
cell polarity. Additionally, the downregulation of Rac1 activity of RAS-transformed or 
phorbol-ester-stimulated Madin-Darby canine kidney (MDCK) cells leads to the loss of 
epithelial-cell junctions and a more mesenchymal and motile phenotype (Zondag et al., 
2000). In some cells, activation of Rho proteins can contribute to the loss of adherens 
junctions; in fact, the ability of TGF-β to promote the loss of adherens junctions is 
dependent on Rho and ROCK function (Bhowmick et al., 2001) and in keratinocytes, 
active Rac1 leads to the dis-assembly of adherens junctions (Braga et al., 2000). 
Furthermore, increased motility and the ability to remodel the ECM are required for 
tumour cells to become locally invasive. RhoA and Rac1 can regulate the function of ezrin 
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(a characteristic of astrocytes (Pujuguet et al., 2003), moesin (localised to filopodia and 
membraneous protrusions that are important for cell-cell recognition, signalling and for 
cell movement) and radixin (links actin to plasma membrane): these related proteins are 
known to promote cell motility by linking the actin cytoskeleton to the plasma membrane 
through CD44. RhoA promotes phosphorylation of ezrin by ROCK leading to its increased 
association with the cytoskeleton (Matsui et al., 1998) whereas Rac1 promotes the 
phosphorylation and inhibition of the ezrin antagonist neurofibromatosis 2 (Shaw et al., 
2001; Xiao et al., 2001). RhoA and Rac1 can modulate the degradation and remodeling of 
the ECM either by regulating the levels of matrix metalloproteinases (MMPs) that degrade 
the ECM or by regulating the levels of their antagonists, tissue inhibitors of 
metalloproteinases (TIMP) (Zhuge et al., 2001; Engers et al., 2001; Kheradmand et al., 
1998; Matsumoto et al., 2001). The ability to enter either the blood or the lymphatic 
vasculature is required for tumour cells to metastasize to distant sites. RhoA and ROCK 
are required in both the endothelial and the migrating cells for them to cross the vascular 
endothelium (Worthylake et al., 2001; Adamson et al., 1999). It was demonstrated that 
overexpression of RhoC leads to increased levels of angiogenic factors in breast epithelial 
cells (Van Golen et al., 2000) which could lead to increased vascularisation of the tumour 
and increased likelihood of tumour cells to enter the blood stream. High levels of RhoC 
also promote the ability of melanoma cells to exit the blood and colonise the lungs (Clark 
et al., 2000). 
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Figure 11: Involvement of RHO proteins at different stages of tumour progression. (a) 
maintenance of normal epithelial polarity. (b) benign tumours: loss of polarity and 
multilayering. Inhibition of RAC1 leads to failure to deposit laminin asymmetrically and 
subsequent loss of polarity. Activation of RHOA also leads to loss polarity but antagonism of 
RHOA function by RHOE/RND3 overexpression which leads to multilayering of epithelial 
cells (c) locally invasive tumours: loss tissue boundaries and increased motility-modulation of 
RAC1 and RHO/ROCK activation can lead to loss of cell-cell junctions. Elevated activity of 
RHOA, ROCK, RAC1 regulate expression of proteases that facilitate motility by degrading 
the basement membrane and other extracellular matric compounds (d)  metastasis to distant 
site: intravasation and extravasation. RHO and ROCK are required for tumour cells to cross 
endothelial cell layers. RHOC promotes expression of angiogenic factors, leading to an 
increase in vascularisation of the tumour (Sahai and Marshall, 2002). 
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1.13.3 Rho GTPases in brain tumours 
The Rho-family GTPases namely Cdc42, Rac1 and RhoA are major regulators of actin 
cytoskeletal organization and play a crucial role in many cellular processes, including cell 
migration (Etienne-Manneville and Hall, 2002; Nobes and Hall, 1999). All three of these 
GTPases have also been shown to influence invadopodia regulation although in different 
cell types (Berdeaux et al., 2004; Chuang et al., 2004; Yamaguchi et al., 2005). In glioma 
cells namely SNB-19 and U87MG, depletion of Rac1 or its effector, synaptojanin 2, using 
siRNA inhibited invasiveness of cells through slices of rat brain tissue and through 
matrigel (Chuang et al., 2004). Senger and collegues (2002) showed that Rac1 regulated an 
important survival pathway in most glioma cells and that suppression of Rac1 activity 
stimulated the death of almost all glioma cells irrespective of p53, MDM2 or EFGR 
mutation or amplification status. The results thus suggest that mutation in effector region 
of Rac1 gene may be related with some brain tumours of different metastasic potential 
(Hwang et al., 2004). Rac 1 is known to be a critical regulator of glioma motility and 
invasion (Salhia, 2006). 
It has been reported that there is an increase of RhoA expression in high-grade 
astrocytomas (Yan et al., 2006). RhoA and RhoB expression is, however, inversely 
correlated with tumour grade in glioma (Forget et al., 2002). In addition, inhibition of 
ROCK has been reported to increase motility of GBM cells with associated membrane 
ruffling and collapse of actin fibres (Salhia et al., 2005). Furthermore, recent data have 
shown that the suppression of GBM cell motility by olig2 occurs via activation of RhoA 
(Tabu et al., 2007). 
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Studies by Mira and colleagues (2000) showed that Rac3 was overexpressed in 33% of 
meningiomas, 17% of pituitary adenomas and 9% astrocytomas and that the higher 
expression of Rac3 in meningiomas may be related to the involvement of a steroid 
hormone receptor in meningioma biology. Later, the expression of Rac3 was also found in 
glioblastoma multiforme, raising the possibility of a functional role of Rac3 in this tumour 
(Hwang et al., 2005). This may further suggest that high expression of Rac3 is related to 
aggressive behaviour of both meningioma and astrocytoma. 
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1.14 Plan of investigation
The precise location of CD44 and CD155 will be established in a range of human biopsy-
derived GBM cell cultures. In the second part of the project, the effects of siRNA ‘knock-
down’ of CD44 and CD155 both individually and in combination will be evaluated in the 
context of the degree of invasion of brain tumour cells. The interactions of silenced CD44 
and CD155 with subunits of integrins will be examined as well as their effects on RHO 
GTPases signaling pathway.
1.14.1 Hypotheses
1. That the poliovirus receptor (CD155) influences brain tumour cell invasion.
2. That a co-operative role exists between the hyaluronic acid receptor (CD44) and 
poliovirus receptors (CD155) in modulation of tumour cell invasion.
1.14.2 Aims
1. To characterise the expression of CD44 and CD155 both qualitatively and 
quantitatively on range of human biopsy-derived GBM cell cultures and non-
neoplastic astrocytes.
2. To show whether the two molecules are located closely on the cell membrane of 
human biopsy-derived GBM cell cultures.
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3. To demonstrate that CD44 and CD155 expressing cells demonstrate an invasive 
phenotype in human biopsy-derived GBM cell cultures.
4. To show that inhibition of these two molecules results in modification of invasive 
behaviour in human biopsy-derived GBM cell cultures.
5. To show that inhibition of CD44 and CD155 results in alterations in migration and 
velocity of cell movement.
6. To demonstrate that inhibition of CD44 and CD155 results in altered proliferative 
rate of GBM cell cultures under study.
7. To show that knock-down of CD44 and CD155 causes differences in adhesion 
potential on different extracellular matrices.
8. To show the interactions of CD44 and CD155 with F-actin and different subunits of 
integrins.
9. To show that inhibition of CD44 and CD155 affects the expression level of RHO 
GTPase proteins.
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1.14.3 Objectives
The aims will be carried out by:
1. Characterisation of level of expression and respective distribution of CD44 and 
CD155 by single and double staining in the following glial/glioma cell lines: 
UPAB, UPMC, SNB-19 (gliomas) and CC-2565 (non-neoplastic astrocytes) by 
flow cytometry and ICC using appropriate  antibodies to CD44 and CD155.
2. To examine cells with a Zeiss Aviovert microscope incorporating total internal 
reflected fluorescence (TIRF) to permit high signal, low noise-fluorescence 
imaging of the CD44 and CD155 epitopes within tumour cell membranes with 
great clarity and resolution.
3. To assess the invasive potential of CD44 and CD155 through 8µm porosity 
TranswellTM Boyden chamber filters and characterise the invasive cells by ICC 
detection with alkaline phosphatase substrate.
4. To determine whether by blocking CD44 and CD155 with specific monoclonal 
antibody both in combination or individually, invasion was inhibited using a
TranswellTM Boyden chamber system.
5. To establish whether the RNAi knockdown of CD155 in glioma cells alters cell 
morphology with resultant reduction in migration and to enable tracking 
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directionality and speed of movement through the live cell (time-lapse) 
microscopy.
6. To assess the adhesive potential of CD44 and CD155 through a fluorometric 
adhesion assay on untreated cells versus MAb blocking and siRNA- treated cells.
7. To investigate whether MAb blocking and siRNA- treated cells of CD44 and 
CD155 have an effect on proliferative rate of cells assessed by BrdU proliferation 
assay.
8. To evaluate the interactions of integrins and F-actin on CD44 and CD155 silenced 
cells using confocal microscopy.
9. To investigate the molecular mechanisms and effects of GTPase activation in CD44 
and CD155 siRNA ‘knockdown’ cells by Western blotting.
53
CHAPTER TWO
MATERIALS AND METHODS
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2.1 Human authentication PCR
Hughes and colleagues (2007) pointed out that cellular cross contamination with other cell 
lines and even species contribute to misleading results. Thus, to confirm that the short term 
and long term cell cultures were of human origin and had not been contaminated with 
mouse or rat cells, the TEST-ITTM Kit from Microzone Ltd (Haywards Heath, UK) was 
used. The whole experiment and testing of the cell lines was performed by Dr Samantha 
Higgins (PhD). 
2.1.1 Mitochondrial DNA extraction
Mitochondrial DNA was first extracted from the cells using microLYSIS®-PLUS (MLP) 
(Microzone, Ltd, UK). Cells were harvested and 1x104 cells were then mixed with 20 µl 
MLP and the total volume made up to 30 µl using MLP. The negative control was 10 µl 
water added to 20 µl MLP and the positive human control DNA was supplied by 
Microzone Ltd. Samples were then placed in the thermal cycler (Px2 Thermal cycler, 
Thermo Electron Corporation).
The cycling profile was as follows (1x cycle):
Step 1: 650C for 15 minutes
Step 2: 960C for 2 minutes
Step 3: 650C for 4 minutes
Step 4: 960C for 1 minute
Step 5: 650C for 1 minute
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Step 6: 960C for 30 seconds
Step 7: 200C hold
After cycling, the extracted DNA was used for further PCRs or stored at -200C for future 
use. Throughout this protocol all apparatus and molecular grade water (Sigma Aldrich, 
UK) used were sterile and DNAse/RNAse-free.
2.1.2 Preparation of controls for PCR
Human DNA controls were supplied by Microzone Ltd, mouse and rat DNA controls were 
produced in-house from mouse and rat tails under Home Office Animals (Scientific) Act 
1986 (UK) (Higgins et al., 2010). The extraction of genomic DNA from mouse and rat 
tails was achieved by utilizing the ‘Quick Extraction of Genomic DNA from Mouse Tail 
Kit’ (BioPioneer Inc, USA). Small sections approximately 0.2cm were cut from both 
mouse and rat tails and placed in 100µl of solution A and incubated at 960C for 30-60 
minutes. The sample was chilled to room temperature and vortexed to mix. 100µl of 
solution B was added to the samples and vortexed again to mix. 1-2µl of this mixture was 
then used to run PCR amplification directly or stored at -200C.
2.1.3 TEST-ITTM Kit
The TEST-ITTM kit (Microzone Ltd, UK) consisted of MegaMix~Gold (MMG) and 
PrimerMix 3* (PM3*) and a 100 base pair (bp) DNA ladder for one test; 12.5µl MMG + 
10.5µl PM3* was required to make the working mix. For multiple tests, volumes 
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calculated were multiplied by sample number plus one. 2µl of DNA to be tested (0-10ng) 
(or 2µl water for the blank) was added to 23µl working mix and placed in the thermal 
cycler.
The amplification was as follows:
Initial denaturation step: 950C for 5 minutes then cycled 30 times:
Step 1: 950C for 30 seconds
Step 2: 630C for 30 seconds
Step 3: 720C for 45 seconds
Step 4: 200C hold
2.1.4 Gel Electrophoresis of PCR Products
Reagents: Stock solution 50X TAE buffer (Tris-acetate +EDTA)
242g TRIS (hydroxymethyl)aminomethane (Sigma Aldrich, UK)
57.1ml Glacial Acetic (Sigma Aldrich, UK)
100mls EDTA 0.5M (pH 8) (Sigma Aldrich, UK)
100 mls EDTA 0.5M (pH 8)
18.61g EDTA (Sigma Aldrich, UK)
80mls dH2O (in-house)
Adjust with NaOH (Sigma Aldrich, UK) to pH 8 and make up to 100 mls
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After cycling, 10µl of PCR product + 4µl DNA loading buffer (Bioline, UK) was loaded 
onto a 1.7% agarose gel and electrophoresed alongside 10µl of the 100bp ladder. The bio-
Rad ‘sub cell’ was utilized for all agarose gel electrophoresis work.
1.7% agarose gel (Bioline, UK) =1.9125g agarose in 2.25 mls 50x TAE Buffer + 110.25 
mls molecular grade distilled water. This solution was placed in a microwave oven for 
approximately 2 minutes until boiling and cleared. Once the solution had cooled enough to 
handle, 3µls (10mg/ml) ethidium bromide (Promega, UK) was added before the gel 
polymerized to enable DNA visualization under ultraviolet light. After casting, the gel was 
allowed to solidify for approximately one hour. The gel was placed into the tank and 600 
mls of 1x TAE buffer was added, the comb was then removed from the gel. Samples were 
loaded onto the gel and run at 90 volts for 1 hour. The gel was examined under UV light 
and visualized on the ‘Chemi Genius’ bio imaging system and imaged using the software 
Genesnap (Syngene, UK). An image was captured after adjusting for sharpness and light 
intensity and the size of the separated fragments was estimated by comparing to the species 
controls and the 100bp DNA ladder. 
The expected fragment sizes for the human authentification PCR were as follows:
 DNA from human: 200, 300 and 500bp
 Mouse DNA: 150, 350 and 500bp
 Rat DNA: 250, 450 and 500bp
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2.2 Cell culture and cell lines
All cell culture work was carried out aseptically in a sterile laminar flow cabinet 
(NUAIRETM Biological safety cabinets, Class II). All glasswares used for tissue culture 
was previously autoclaved to ensure sterility. All materials to be used in the cabinet were
sprayed with 70% ethanol (prepared in-house) to maintain a sterile environment. Cell lines 
used were cultured in complete medium: Dulbecco’s Modified Eagle Medium (DMEM-
without pyruvate, with Glucose, Glutamax and Phenol Red) (Gibco, UK), supplemented 
with 10% heat-inactivated foetal calf serum (FCS) (Sigma Aldrich, UK). Subsequently, 
cells were passaged to fresh culture flasks: T25 and T75 (Greiner Bio One, UK) every 3-5 
days, uplifting cells with TrypLETM Express (Invitrogen, UK) after washing with Hank’s 
Balanced Salt Solution (HBSS) (Invitrogen, UK). Cell cultures were maintained in a 
humidified incubator (NUAIRETM DH AUTOFLOW CO2 Air-Jacketed) supplied with 5% 
CO2 and 95% air at 37
0C. The passage number of the cells was increased by one on
subculturing. 
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Table 2 Primary cell cultures and cell Lines used
Cell Lines Histological Grading & 
characteristics 
Sex of 
Patient
Age of patient at 
time of surgery
CC-2565 Non- Neoplastic Human 
Foetal cerebral Astrocytes
Male 18 weeks
UPAB Low passage, heterogenous 
Grade IV GBM 
Male 72 years
UPMC Low passage, heterogenous 
Grade IV GBM 
Female 68 years
SNB-19
/U251MG
High passage, established  
Grade IV GBM 
Male  75 years
Table 2 shows low passage cell cultures, denoted with ‘UP’ were established ‘in 
house’ from biopsies received from surgical resections. SNB-19 was purchased from 
the DSMZ German Brain Tumour Bank, Germany and CC-2565 were from Lonza, 
UK.
2.2.1 Establishment of Primary Cultures
Human tumour biopsies were obtained from excised gliomas or from biopsies of tumours 
of patients from King’s College Hospital (London, UK), with ethical approval obtained; 
LREC 00-173 and 02-056. On receipt, biopsies were transferred to a sterile petri dish and 
rinsed with HBSS. Blood clots, blood vessels and necrotic tissues were removed with 
sterile scalpels; the tissue was then dissected into small fragments until a uniform 
suspension was obtained. The suspension was then transferred into T25 tissue culture 
flasks containing DMEM + 20% FCS + 1% penicillin/streptomycin (Invitrogen, UK), left 
to adhere for 3-4 days. On day 4, the media was removed and washed with HBSS. 
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Subsequent cells were visualised using an Olympus 1X71 inverted Phase Contrast 
Microscope. All primary cultures used were established in this way at the University of 
Portsmouth except CC-2565 (purchased from Lonza, UK) and SNB-19 (DSMZ German 
Brain Tumour Bank, Germany).
2.2.2 Cryopreservation of cell cultures
RecoveryTM cell culture freezing medium (Invitrogen, UK) was supplied complete with 
dehydrating agent DMSO. This agent is a cryoprotective as it reduces the water content of 
the cells thus reducing ice crystal formation and hence preventing damage to cell 
membranes. Cells were harvested as previously described, centrifuged and resuspended in 
1 ml of freezing medium which was then transferred to a cryotube. Cell freezing began 
within 5 minutes of this point; the cryotubes were placed in a ‘Mr Freezy’, a controlled 
freezing container which allowed the cells to cool at a rate of 10C/minute; in a -800C 
freezer overnight. Afterwards the cells were immersed in liquid nitrogen at -1960C and 
stored for an indefinite period.
2.2.3 Resurrection of cells from liquid nitrogen tank
Required cells were taken from liquid nitrogen tank, thawed rapidly at 370C and cultured 
to a T75 tissue culture flask where 9 mls of complete medium was added in a drop-wise 
manner to avoid the cells bursting due to changes in osmolarity. Media was changed after 
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24 hours incubation to remove dimethyl sulfoxide (DMSO), returned to the incubator for 
storage and maintained in a normal way until 80-100% confluency was reached.
2.2.4 Cell counting and seeding densities determination
It is important to determine the number of cells within a flask before beginning any 
experiment, as per required for certain procedures. An automated ViCellXR Cell Viability 
Analyzer (Beckman Coulter, UK) utilising the trypan blue exclusion assay was used to 
determine cell number and cell viability. The protein binding dye, Trypan Blue is taken up 
passively and retained by dead cells. In this way, dead cells can be differentiated from 
viable ones and the machine can distinguish between these to give an accurate 
quantification of cell number and viability. To perform a routine count, cells were 
harvested, centrifuged and resuspended in 1 ml of complete media from which 100 µl of 
cell suspension was removed and placed in a sample cuvette with 500 µl of complete 
media. This was then transferred to the ViCell analyser and the cell count carried out. To 
determine the volume of cell suspension required for a pre-determined cell number 
(seeding densities) to start an experiment, the following equation was used:
1000 X (Number of cells required)     = required volume (µl) of the cell suspension.
Total number of viable cells counted
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Figure 12: Vi-CELLTM XR data collected for UPAB cells. The total viable cell count 
was 3.31 x 106 cells/ml and the percentage viability was 98.3%.
2.2.5 Growth curves
Growth curves were used to monitor cell growth and consistency of cells. This technique 
helped to know optimal time to passage cells, determining correct seeding densities and 
plating efficiency. From a growth curve, the lag time, population doubling time (log or 
exponential phase) and the saturation density (stationary phase or plateau) can be 
determined. 
Cells were harvested, counted using the ViCell XR Cell Viability Analyser and initially 
plated at three different concentrations: 1x103 cells; 1x104 cells; 1x105 cells in triplicate in 
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T25 flasks for each concentration to determine the optimal seeding density of each cell line 
used in the scope of this thesis and this procedure was considered as Day 1. The flasks 
were then returned in the incubator. Sampling was repeated at 24 hour intervals until a 
plateau was reached (no increase in cell concentration noted in the flasks). The resulting 
cell densities were plotted against time and the population doubling time (PDT) calculated.
2.3 Flow cytometry
Cells were harvested, centrifuged, resuspended in 1ml PBS (Sigma Aldrich, UK) + 5% 
FCS (Sigma Aldrich, UK) and split into four eppendorf tubes. Four eppendorf tubes were 
sufficient to allow one antibody stain in triplicate and a negative control; all tests were 
repeated at least three times. The eppendorf tubes were centrifuged at 1000 rpm/100g using 
an Eppendorf 5415R microfuge for 5 minutes, the supernatant discarded and the samples 
incubated with 100µl cytofix/cytoperm solution (BD Biosciences, UK) for 20 minutes at 
40C (except for extracellular/cell surface antigens which do not require permeabilisation 
and so cytofix/cytoperm was not used). This allows the permeabilisation of membranes in 
order to allow interaction of the antibody with its intended target. Samples were then 
subjected to washing with 500µl PBS prior to incubation with 100µl pre-diluted primary 
antibody for 40 minutes at 40C. This step was omitted for the negative control samples. 
Samples were washed with 500µl buffer (PBS + 5% FCS), centrifuged and the supernatant 
discarded. Samples were then resuspended in 100µl secondary Alexa Fluor 488 
(Invitrogen, UK) conjugated antibody for 20 minutes in the dark at 40C. Samples were then 
washed, centrifuged and the supernatant discarded. Cell pellets were resuspended in 300µl 
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(test samples) and 500 µl (control samples), transferred to FACS tubes (BD Biosciences, 
UK) and analysed. Before analysis, 5µl propidium iodide (PI) (Sigma Aldrich, UK) was 
added to samples probing cell surface antigens, in order to stain the nucleus, therefore 
gating out the dead population of cells (except for intracellular antigens which do not 
require PI). To statistically validate the results, each sample was assayed in triplicate (1 
control + 3 positives) in at least three independent experiments.
Analysis was performed on a four colour multi parameter BD Biosciences FACS Calibur 
equipped with a 488nm argon gas laser and a 635nm red diode laser. Emission 
fluorescence was collected via a system of optical mirrors and filters and the specified 
wavelengths of the collected light routed to designated optical detectors. For Alexa Fluor 
488/FITC, this was measured using a 530/30nm filter and emission fluorescence for PI was 
measured using a 670nm LP filter. Acquisition/analysis was performed using CellQuest 
Pro software. 
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Table 3 Primary and Secondary Antibodies used for Flow cytometry
Primary 
Antibody
Dilution Company Secondary 
Antibody
Dilution Company
CD44 1:25 Chemicon Goat anti-mouse 
Alexa Fluor 488  
IgG
1:500 Invitrogen 
CD155 1:20 R&D 
Systems
Goat anti-mouse 
Alexa Fluor 488  
IgG
1:500 Invitrogen
GFAP 1:20 Dako Goat anti-rabbit 
Alexa Fluor 488  
IgG
1:500 Invitrogen
β1 integrin 1:70 Abcam Goat anti-rabbit 
Alexa Fluor 488  
IgG
1:500 Invitrogen
F-Actin-
conjugated 488
1:40 Invitrogen Goat anti-mouse 
Alexa Fluor 488  
IgG
Table 3 lists the details of primary and secondary antibodies with their corresponding 
species and dilution used for flow cytometry.
Pre-diluted by 
the supplier
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2.3.1 Statistical analysis 
Statitistical analysis was performed on the data using one-way ANOVA followed by 
Tukey’s multiple comparison post test with a probability of less than 0.05 being regarded 
as significant. The software package GraphPad Prism 3.02 was used to calculate the 
statistical tests where all data are expressed as mean values.
2.4 Immunocytochemistry
Cells were harvested from confluent tissue culture flasks and seeded onto sterile 13mm 
glass coverslips (VWR, UK) within a six well plate at an approximate density of 1x105
and allowed to reach 70-80% confluency before immunostaining. Cells were fixed with 
4% paraformaldehyde (PFA) (Sigma Aldrich, UK), pH 7.4 for 5 minutes with three 
subsequent washes in PBS before proceeding to immunocytochemistry. Prior to primary 
antibody incubation, cells were blocked with 10% normal serum (species dependent on 
secondary antibody used) in PBS for 1 hour with 0.2% Triton X-100 (Sigma Aldrich, 
UK) for 10 minutes at room temperature (except extracellular antigens which do not 
require permeabilisation thus no Triton X-100 was used). All antibodies were diluted in 
blocking solution and primary antibodies were incubated for one hour at room 
temperature. Secondary conjugates were incubated at 1:500 dilution at room temperature 
in the dark for 30 minutes. Nuclei were counterstained with Hoechst Blue (Sigma 
Aldrich, UK) diluted 1:100 for approximately 20 seconds before coverslips were 
mounted with Vectashield® (Vectorlabs, UK). Washes were carried out in PBS (5 
minutes x 3) before and after each antibody incubations and where double 
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immunolabelling was carried out, antibodies (raised in different hosts) were cocktailed 
for both incubation steps. For the control, no primary antibody was added followed by 
secondary antibody and the specificity of the antibodies were tested as follows:
CD44: Same antibody purchased from different companies and tested through ICC and 
Flow cytometry.
CD155: C6 glioma cells were stained for CD155 (used as control and specificity since 
CD155 is only expressed in primates)
Table 4 Primary and secondary antibodies used with their corresponding blocking 
and buffers
Primary 
Antibody
Dilution Species Secondary Antibody Dilution Blocking 
serum 
CD44 1:500 Mouse 
anti-human 
Goat anti-mouse 
Alexa Fluor 488/568  
IgG2a
1:500 10% Goat 
serum
CD155 1:200 Mouse 
anti-human
Goat anti-mouse 
Alexa Fluor 488/568  
IgG1
1:500 10% Goat 
serum
GFAP 1:200 Rabbit 
anti-human
Goat anti-rabbit Alexa 
Fluor 488  IgG
1:500 10% Goat 
serum
Table 4 gives the details of the primary and secondary antibodies with their 
respective dilution and blocking serum used for ICC.
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2.4.1 Epi-fluorescence microscopy
The slides were viewed using a Zeiss Axiomager Z1 fluorescence microscope equipped 
with a Hemamatsu digital camera (C4742-95) with GFP/FITC (AF 488-green) and Texas 
red (AF 568-red) and DAPI (HB-blue) filters to detect fluorescence from labeled cells. 
Areas of interest were chosen by observing the slides at x10 and then closely examined at 
x20 & x40 and images were captured using Velocity 4 software (Improvision).
2.5 Total Internal Reflected Fluorescence (TIRF) Microscopy 
Specimens were examined with a Zeiss Aviovert 200M incorporating total internal 
reflected fluorescence (TIRF) microscope which permitted high signal, low noise 
fluorescence imaging within the tumour cell membrane with great clarity and resolution. 
Samples were processed as mentioned in section 2.4 however mounting media used had to 
be of the same refractive index of water. In this case citifluor (Agar Scientific, UK) was 
used to mount the coverslips onto the slides. Fluorescence was detected using excitation 
wavelengths of 488nm (green), 568nm (Red) and 405nm (blue) with an argon ion laser. A 
x100 oil immersion objective with a high numerical aperture objective (NA > 1.3) was 
used to obtain TIRF images. Images were taken after the correct internal reflectance angle 
was identified. The TIRF microscope only excites fluorophores which are 50-75 nm from 
the coverslip and images were captured using the Axiovision software. 
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2.6 Invasion assay
Invasion assesses the motility of cells and their capacity to adhere to and digest the 
extracellular matrix in order to invade through. Cell invasion was assessed through the 
TranswellTM modified Boyden Chamber assay. Cells were grown in serum free media. The 
TranswellTM inserts used were 8µm porosity, polycarbonate membrane filters within 24-
well plates (Corning, UK) and were coated with 50µl (0.5mg/ml) of thawed BD 
MatrigelTM (Scientific laboratories supplies, UK) then left to dry overnight in the laminar 
flow hood. The coated inserts were rehydrated the following day with 70µl cold serum 
free media (SFM) and left for one hour at 370C. 10ng/ml platelet-derived growth factor 
(PDGFAB) (Universal Biologicals Cambridge, UK) diluted in SFM was used as a 
chemoattractant and added to the lower chamber of the well. Cells were harvested, counted 
and seeded at a concentration of 1x105cells/100 µl SFM in the upper compartment of the 
transwell unit. Invasion was allowed to occur for 6 hours at 370C in a 5% CO2 chamber. 
The filters were then removed and fixed with 4% PFA. Non-invading cells on the upper 
surface of the filter were removed with a cotton swab and invaded cells, adherent on the 
lower filter surface were characterised through alkaline phosphatase vector red 
(Vectorlabs, UK) staining. Nuclei were counterstained with Haematoxylin (Dako, UK). 
Images were captured by a Zeiss Axiophot brightfield microscope using the Axiovision 
release 4.4 software and cells were counted in 5 random fields. Each experiment was 
performed in triplicate. 
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Figure 13: Diagrammatic representation of cross section of a TranswellTM Boyden 
chamber set-up for an invasion assay (Pilkington, 1996). However, 0.5 mg/ml of 
matrigel was coated on the membrane filter 24 hours prior the invasion assay.
2.7 Monoclonal Antibody Blocking assay 
The monoclonal blocking assay was assessed through the TranswellTM Boyden chamber 
assay. A normal invasion assay was carried out as explained in section 2.6 however in the 
upper compartment of the transwell inserts, 100 mg/ml of Monoclonal antibody 
(Cambridge Biosciences, UK) was added and incubated for 6 hours at 370C and 5% CO2. 
This step was omitted for the negative control. The positive controls used to validate the 
blocking antibody specificity were: CD44 (Chemicon, UK) and CD155 (R&D systems, 
UK). These were commercially available monoclonal antibodies used for ICC and flow 
cytometry. The filters were then removed and fixed in methanol. Invaded cells on the 
lower filter surface were stained with Diff Quick (BDH Laboratory Supplies, UK) and 
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cells were counted in 5 random fields. Each experiment was performed in triplicate. Mean 
values of invaded cells for each point were calculated. Invasion was expressed as mean ± 
SEM of the number of total cells counted per well.  To note: A time-point analysis (2hr, 
4hr, 6hr, 8 hr, 10hr) was carried out before choosing ‘6 hours’ as the optimal incubation 
time for the blocking assay which was further supported by previous papers (Pilkington et 
al., 1993). 
2.7.1 Statistical analysis 
Statitistical analysis was performed on the data using one-way ANOVA followed by 
Tukey’s multiple comparison post test with a probability of less than 0.05 being regarded 
as significant. The software package GraphPad Prism 3.02 was used to calculate the 
statistical tests where all data are expressed as mean values.
2.8 Transfection of cells with siRNA CD44 and siRNA CD155
The introduction of siRNA for a particular gene is used to evaluate gene knock-down. 
However the key step for maximum transfection efficiency and minimal cytoxicity is the 
efficient delivery of nucleic acids to the cells. AccellTM siRNA and reagents (Thermo 
Scientific Dharmacon, UK) was used to achieve transfection. These siRNAs were 
specifically modified for use without a transfection reagent and work at a higher 
concentration than the conventional siRNA with minimal disruption of the expression 
profile and when used with Accell siRNA delivery media, little or no delivery optimization 
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was required. The AccellTM siRNA control kit (Thermofisher scientific, UK) was used to 
test for target specificity, stability and successful uptake of the siRNAs by cells. The 
controls used were as follows:
Table 5: Positive and negative controls used for validation of transfection studies:
Target gene Accession number Description
GAPD NM_002046 Species-specific control siRNAs 
designed to silence target genes.
Table 5.1 shows the positive control used to validate the results from the 
transfection studies. GAPD siRNA was used as a house-keeping gene.
Primer name Description
Accell non-targeting 
pool siRNA
Negative control pool of 4 siRNA with at least 4 mismatches 
to any human, mouse or rat gene. Designed not to target any 
genes in the human, mouse or rat genomes.
Table 5.2 shows the negative control used as a validation of the transfection studies.
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Table 6 RNA sequences of AccellTM siRNA used in the transfection studies
Primer Name: Accell SMARTpool 
siRNA CD44
Target sequence
A-009999-14, CD44 CUC UGA GCA UCG GAU UUG A
A-009999-15, CD44 CCA UUC ACC UUU AUG UUA U
A-009999-16, CD44 CCU UUG AUC AGU AUA AUU U
A-009999-17, CD44 CUG UUA UAU CAG AGG AGU A
Table 6.1 shows primer name and sequence of each siRNA primer. The primers were 
supplied as SMARTpool® siRNA (Dharmacon, UK). On receipt of siRNA Duplexes, 
they were resuspended in 100µl 1 X siRNA buffer to make a 100µM solution as per 
the manufacturer’s guide.
Primer Name: Accell SMARTpool 
siRNA CD155
Target sequence
A-015323-13, PVR GGA UCG GGA UUU AUU UCU A
A-015323-14, PVR CUA UGA UCU UGA GGG CAG A
A-015323-15, PVR UCU UUG UGU CCA GAG UUU U
A-015323-16, PVR GGU GCA AGU UCA UAG GUC U
Table 6.2 shows primer name and sequence of each siRNA primer. The primers were 
supplied as SMARTpool® siRNA (Dharmacon, UK). On receipt of siRNA Duplexes, 
they were resuspended in 100µl 1 X siRNA buffer to make a 100µM solution as per 
the manufacturer’s guide.
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Transfection reagents affect viability of cells, in particular in antibiotic containing media, 
therefore, 48 hours prior to transfection, media was changed to antibiotic free medium and 
weaned onto to Accell siRNA delivery media (Dharmacon,, UK) and 3% FCS. Cells were 
harvested and plated into 96 well plates at an approximate seeding density of 1x104 to 
achieve 90% confluency at the time of transfection (All amounts and volumes are given on 
a per well basis for 96 well plate formats and can be scaled up or down for other well 
formats). 7.5µl of the 100µM siRNA was mixed with 750µl delivery media resulting in a 
final concentration of 1µM Accell siRNA per well. The growth media was removed from 
wells and replaced with 100µl of the delivery mix (Accell siRNA and Accell delivery 
media) per well. Plates were then returned to the incubator for 96-120 hours and gene 
knock-down was evaluated.
2.9 Western blotting
Cells were washed with PBS before 250µl of the lysis buffer was added to the cells. The 
lysis buffer was comprised of 1ml of RIPA buffer (Thermofisher, USA) and 10µl HaltTM
Protease and Phosphatase Inhibitor cocktail. The flask was transferred immediately on ice 
and left to incubate for 5 minutes on a plate shaker (Platform Shaker STR6, UK). The cells 
were scraped off the substrate and the lysate was used for protein quantification which was 
carried out using the Bradford protein assay (Dako, UK) with a standard curve bovine 
serum albumin (BSA) concentration curve constructed. Samples were mixed with Laemmli 
sample buffer (Biorad, UK) with β-mercaptoethanol and 20µg of protein per lane were 
loaded for 10% acrylamide SDS-PAGE. Proteins were then electrophorectically transferred 
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to a polyvinylidenefluoride (PVDF) membrane (Biorad, UK) which was then incubated in 
blocking solution: 0.5-5% dried milk in Tris buffered saline (TBS; 150 mM NaCl, 10 mM 
Tris pH 7.4) with 0.05% Tween 20. Primary antibody incubation was carried out overnight 
at 40C and secondary antibody horseradish peroxidase-conjugates added at 1:1000 for one 
hour at room temperature. Extensive washing of the membranes in TBS with 0.05% Tween 
were carried out after each incubation and immunocomplexes were revealed using an 
enhanced chemiluminescence reagent (Cheshire sciences, UK) according to the 
manufacturer’s protocol and light sensitive films (Amersham, UK).
2.10 Proliferation assay
Here, the Bromodeoxyuridine (BrdU) cell proliferation assay kit (Chemicon, UK) was 
used to assess the proliferative rate (S-phase) of the cells under study. As per the 
manufacturer’s guide, two types of control are recommended to insure the viability of the 
experiments, namely blank (only tissue culture supernatant added to the well) and 
background (cells were present but no BrdU reagent added to the well). Cells were seeded 
in a 96 well plate at a density of 2 x 105 cell/ml in 100µl/well of appropriate culture media 
and left to adhere properly for 24 hours at 370C/ and 5% CO2. BrdU was added at least 2 
hours (the time mentioned was related to the population doubling time of the cell line 
under study; refer to section 3.3) prior to the end of the incubation period and pipette 20µl 
of the diluted BrdU label (1:500 of concentrated stock: culture media) to the appropriate 
wells and incubate for 16-18 hours. The labeling solution was removed, 200µl/well of the 
fixing solution was added to the cells and the plate was incubated for 30 minutes at room 
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temperature. The plate was washed 3 x with washing buffer provided in the kit. 100µl/well 
of anti-BrdU monoclonal antibody was added to the wells and incubated for 1 hour at room 
temperature. The plate was then washed 3x with washing buffer and 100µl of goat anti-
mouse IgG peroxidase conjugate was added and incubated for 30 minutes at room 
temperature. The plate was washed again 3x with washing buffer and 100µl/well of 
tetramethylbenzidine (TMB) peroxidase substrate was added and incubated for 30 minutes 
at room temperature in the dark. Positive wells were visible by a blue colour, the intensity 
of which is proportional to the amount of BrdU incorporation in the proliferating cells. The 
reaction was stopped by pipetting 100µl/well of the acid solution provided into each well 
where the colour of the positive wells changed from blue to bright yellow. The plate was 
read using a spectrophotometer microplate reader (POLARstar OPTIMA BMG 
LABTECH) set at dual wavelength of 450/550nm. The higher the optical density (OD) 
reading reflected the higher the BrdU concentration in the sample. All tests were done in 
triplicate and repeated three times to achieve statistical validity.
2.10.1 Statistical analysis
Statitistical analysis was performed on the data using one-way ANOVA followed by 
Tukey’s multiple comparison post test with a probability of less than 0.05 being regarded 
as significant. The software package GraphPad Prism 3.02 was used to calculate the 
statistical tests where all data are expressed as mean values.
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2.11 Adhesion Assay
The ECM cell adhesion array kit (Chemicon, UK) used provided an ECM array microtiter 
plate with a homogenous fluorescence detection format allowing quantitative comparison 
of multiple samples. The ECM Array plate consisted of one 96-well plate with 7 strips 
consisting of 6 different human, ECM-coated wells (Collagen I, Fibronectin, Laminin, 
Tenascin, Vitronectin) and one BSA-coated well. Experimental cells at a density of 3 x 106
cells/ml were seeded onto each of the substrates named above. The plate was then 
incubated for 2 hours at 370C in a CO2 incubator. Subsequently, unbound cells were 
washed away and adherent cells were lysed with 1mol NaOH and detected by the CyQuant 
GR® dye. This green-fluorescent dye exhibits strong fluorescence enhancement when 
bound to cellular nucleic acids. Relative cell attachment was determined using a 
fluorescence plate reader with 485nm and 530nm filter sets. All tests were carried out in 
triplicate and repeated three times.
2.11.1 Statistical analysis
Statitistical analysis was performed on the data using one-way ANOVA followed by 
Tukey’s multiple comparison post test with a probability of less than 0.05 being regarded 
as significant. The software package GraphPad Prism 3.02 was used to calculate the 
statistical tests where all data are expressed as mean values.
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2.12 Confocal Microscopy
Confocal images were captured using the x40 (oil immersion) (Numerical aperture 0.5 and 
1.3 respectively) objective of a Zeiss meta LSM 510 Axioskop2 confocal microscope. 
Fluorescence was detected using excitation wavelengths of 488nm (green), 568nm (red) 
and 405nm (blue), with an argon, HeNe1 and diode laser respectively. Images were taken 
using optimal settings for pinhole diameter, detector gain and offset acquisition to detect 
positive immunofluorescence labeling with minimal background. Multi track image 
capture was used, with two channels so that separate channels could image different 
colours to help prevent any overlap in excitation spectra. Identical settings were then used 
to image negative controls in which the primary antibody was omitted. 
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Table 7 Primary and secondary antibodies used with their corresponding blocking 
and buffers
Primary 
Antibody
Dilution Species Secondary 
Antibody
Dilution Blocking 
serum 
CD44 1:500 Mouse anti-
human
(Millipore) 
Goat anti-mouse 
Alexa Fluor 488/568  
IgG2a 
1:500 10% Goat 
serum
CD155 1:200 Mouse anti-
human
(R&D 
systems)
Goat anti-mouse 
Alexa Fluor 488/568  
IgG1
1:500 10% Goat 
serum
β1 integrin 1:100 Rabbit anti-
human
(Abcam)
Goat anti-rabbit 
Alexa Fluor 488  
IgG
1:500 10% Goat 
serum
αvβ1 integrin 1:200 Mouse anti-
human
(Abcam)
Goat anti-mouse 
Alexa Fluor 488  
IgG3
1:500 10% Goat 
serum
αvβ3 integrin 1:250 Mouse anti-
human
(Abcam)
Goat anti-mouse 
Alexa Fluor 488  
IgG1
1:500 10% Goat 
serum
F-Actin-
conjugated 
488
1:40 Mouse anti-
human
(Invitrogen)
Goat anti-mouse 
Alexa Fluor 488  
IgG
‘prediluted 
by
supplier’
10% Goat 
serum
Table 7.1 gives the details of the primary and secondary antibodies with their 
respective dilution and blocking serum used for confocal microscopy
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To confirm the confocal microscopy results, western blotting was performed on SNB-19 
cells (untreated, siRNA CD44-treated and siRNA CD155-treated). (Method has been 
described in section 2.9)
Primary 
Antibody
Dilution Species Secondary 
Antibody
Dilution Molecular 
weight
F-actin 1:250 Mouse anti-human
(Abcam) 
HRP goat anti-
mouse (Dako)
1:000 43 kDa
αv integrin 1:250 Mouse anti-human
(BD Biosciences)
HRP Goat anti-
mouse (Dako)
1:1000 125 kDa
β1 integrin 1:500 Rabbit anti-human
(BD Biosciences)
HRP Goat anti-
rabbit (Sigma)
1:1000 88 kDa
β3 integrin 1:2500 Mouse anti-human
(BD Biosciences)
HRP Goat anti-
mouse (Dako)
1:1000 104 kDa
Table 7.2 gives the details of the primary and secondary antibodies with their 
respective dilution and expected molecular weights identified used to confirm the 
confocal microscopy results.
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2.13 Live cell imaging (Real-time Kinetic Microscopy)
Live cell imaging permits cells to be maintained in a healthy state and function normally 
on the microscope stage. Live cell imaging chambers effectively combine a cell culture 
incubator with an inverted microscope to provide almost total control of the environment,
the incubator enclosure surrounds the microscope stage, objectives, fluorescence filters and 
transmitted light condenser. Temperature is controlled with an external heating unit and 
carbon dioxide concentration is controlled with a sensing unit coupled to a regulator that is 
fed by a cyclinder of pure gas.
Cells of interest were plated at 30% confluency in a 24 well plate and left to adhere 
overnight prior the experiment. The Zeiss Axiovert 200M live cell (time-lapse) microscope
was then set up to image 1 point in each well, once every 30 minutes over 72 hours using 
the DAPI filter to monitor cells under treatment. The images were collated and a movie 
sequence generated. Tracking of cells for speed of movement and distance moved were 
enabled using the Volocity 4 software. 10 cells were tracked randomly for each well and 
each experiment was done in triplicate and repeated three times.
2.13.1 Statistical analysis
Statitistical analysis was performed on the data using one-way ANOVA followed by 
Tukey’s multiple comparison post test with a probability of less than 0.05 being regarded 
as significant. The software package GraphPad Prism 3.02 was used to calculate the 
statistical tests where all data are expressed as mean values.
82
2.14 Signal Transduction Pathways
The Rho family of small GTPases, including Rho, Rac and cdc42, acts as molecular 
switches to regulate processes such as cell migration, adhesion, proliferation and 
differentiation. 
The Rho-GTPase Antibody sampler kit (Cell signaling Technology, UK) was used in the 
scope of this thesis. Cells (under different treatment regimes) were subjected to Western 
blotting (as described in section 2.9)
Table 8 Primary and secondary antbodies used with their corresponding dilutions
Primary 
Antibody
Dilution Species Secondary 
Antibody
Dilution Molecular 
weight
Cdc42 1:250 Rabbit anti-
human 
HRP Goat anti-
rabbit
1:000 21 kDa
Phospho-
Rac/cdc42
1:100 Rabbit anti-
human
HRP Goat anti-
rabbit
1:1000 28 kDa
Rac 1/2/3 1:500 Rabbit anti-
human
HRP Goat anti-
rabbit 
1:1000 21 kDa
RhoA 1:500 Rabbit anti-
human
HRP Goat anti-
rabbit
1:1000 21 kDa
RhoB 1:500 Rabbit anti-
human
HRP Goat anti-
rabbit
1:1000 21 kDa
RhoC 1:500 Rabbit anti-
human
HRP Goat anti-
rabbit
1:1000 21 kDa
Table 8 gives the details of the primary and secondary antibodies with their 
respective dilution and expected molecular weights identified used for signal
transduction pathways analysis
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2.15 Statistical significance
Unless stated otherwise, all experiments were done in triplicate and the appropriate 
statistical analyses employed to ensure statistical validity.
